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Methods of Accurate 106Ru and 125I Eye Plaque Dosimetry Using Radiochromic Film in a Solid 
Water “Eye” Phantom and a Small Silicon Diode in a Water Tank 
Samuel Trichter 
Purpose: The use of 106Ru eye plaques for the treatment of intraocular malignancies has produced 
inconsistent clinical outcomes and has even resulted in treatment failures. I hypothesized that 
inconsistent clinical results were attributable to high uncertainties in 106Ru eye plaque dosimetry. 
Furthermore, I hypothesized that more accurate methods for assessing radiation dose from eye 
plaques would lead to more reliable treatment planning and therefore better overall clinical 
outcomes.  
Methods: A Solid Water “eye” phantom with several novel features was developed for 
radiochromic film eye plaque dosimetry. Films perpendicular to the central axis of the eye plaques 
were sandwiched between inserts in the phantom. Small holes in the inserts enabled the film to be 
marked with respect to the eye plaques, assuring exact geometrical co-registration. In cooperation 
with the manufacturer, special thin radiochromic films were developed and utilized to permit 
dosimetric measurements almost at the eye plaque surface. Precise film punches were developed 
for the purpose of cutting films with diameters as small as 8.5 mm and making cutouts in films 
without damaging the cut edges. Findings from a secondary dosimetry system, utilizing a small 
silicon diode in a water tank, were compared to film data. In addition to testing the new dosimetry 
methods with 106Ru eye plaques, which utilize high energy (MeV) β emissions, this approach was 
also applied to 125I containing eye plaques, which due to their inherently lower energy (keV) γ 
emission spectrum, raised additional dosimetric complications. In the latter case dosimetry, films 
and the diode were calibrated for absolute dosimetry using calibrated 125I seeds in Solid Water and 
 
 
water, respectively, applying the TG-43 formalism. A novel calibration method of radiochromic 
film for low-energy photon dosimetry was introduced. Monte Carlo simulations were used to 
convert the results measured in Solid Water to liquid water, and to compare measured and 
simulated dosimetric results. 
Results: Dosimetric characterization of both 106Ru eye plaques and a novel concept 125I eye plaque 
are described. Furthermore, dosimetry of a 20 mm 125I Collaborative Ocular Melanoma Study 
(COMS) eye plaque validated the presumed substantial dose reduction resulting from its gold alloy 
backing and seed carrier insert predicted by Monte Carlo simulations. Dose distributions measured 
with radiochromic film were in good agreement with diode measurements and Monte Carlo 
simulations. Replicate film results were reproducible from 0.9% to 5.5%. As little as 4% non-
uniformities in planar dose rates were easily detected using 106Ru eye plaques. The novel 125I eye 
plaques had uniform dose distributions. Dosimetric characterization of the 20 mm COMS plaque 
demonstrated that the plaque’s dose rate was 15% lower than that predicted by homogenous TG-
43 calculations. Lastly, Monte Carlo simulations indicated dose conversion factors between water 
and film in Solid Water compared to water and Solid Water alone differed by as much as 16.8%. 
Change in the calcium content of Solid Water from 2.3% to 1.7% resulted in a 3.3% calculated 
difference in dose to film and in an 8.7% difference in dose to Solid Water. 
Conclusions: Precise and reproducible 106Ru and 125I eye plaque dosimetry was achieved utilizing 
radiochromic film in a water equivalent phantom and a small semiconductor diode in water. Co-
registration of eye plaques and films permitted not only precise treatment planning calculations 
along the central axis of the plaque, but also made it possible to account for dosimetric non-
uniformities using 2D or 3D methodologies. A calibrated 125I seed enabled calibration of the film 
and the diode for absolute dosimetry of 125I containing eye plaques. Dose measurements on the 
 
 
inner surface of the plaques provided precise assessment of the scleral dose, its homogeneity, and 
of the active area of the plaques for coverage determination. Monte Carlo simulations facilitated 
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1. Introduction/Literature Review. 
Intraocular malignancies, although infrequent, may cause loss of vision and can be life 
threatening1. The two main kinds of primary intraocular tumors are choroidal melanomas and 
retinoblastomas, with approximately 2500 new choroidal melanoma cases and 250 new 
retinoblastoma cases diagnosed annually in the U.S2. Historically, treatment consisted of 
enucleation of the eye; however, retinoblastoma, an early childhood cancer, affects both eyes in 
approximately one third of patients2. Since Stallard3, 4 first used temporarily-applied episcleral eye 
plaques made of 60Co foil, radiation therapy for intraocular tumors has become a viable alternative 
to enucleation. A large number of studies5-29 show that eye plaques provide good local control and 
survival rates similar to or better than enucleation, but with the distinct advantages of eye 
preservation and, in many cases, satisfactory vision outcomes. 
As the names indicate, choroidal melanomas originate in the choroid, while retinoblastomas start 
off in the retina. Intraocular tumors are therefore more commonly located on the posterior aspect 
of the eye. The eye plaque is designed in the form of a cap that is surgically positioned over the 
base of the tumor as shown in Figure 1. 
Each eye plaque has suture lugs or eyelets that allow it to be sutured to the sclera. To assure 
adequate coverage of various tumor geometries, eye plaques are available in diverse sizes and 
shapes. Some eye plaques feature cutout notches for protection of the macula and optic nerve when 
the tumor is located in their proximity or avoidance of iris irradiation when treating ciliary body 
melanomas30. Once an eye plaque of an appropriate size and shape to cover the tumor and provide 
for a margin is selected, it is inserted during a surgical procedure that involves precise positioning 
over the tumor base. After the prescribed dose is delivered over the course of several days, the 




Figure 1. Schematic drawing of an eye showing the main anatomical structures and a melanoma 
originating in the choroid. An eye plaque is placed on the sclera over the tumor base. [Courtesy of 
Chiu-Tsao, S.-T.31 (Figure 2, p. 454).] 
Since the introduction of the first eye plaques using 60Co foil by Stallard in 19613, 4, a range of 
mechanical designs and isotopes have been used. Table 1 below lists the major isotopes that have 
been or are presently in use: 
Isotope Type of Radiation and Average Energy Half-life 
60Co 1.25 MeV photons 5.26 years 
192Ir ~0.38 MeV photons 73.83 days 
198Au 0.412 MeV photons 2.7 days 
125I 28.0 keV (27-35 keV) photons 59.43 days 
103Pd 20.7 keV (20-23 keV) photons  17 days 
90Sr/90Y Beta emitter, 2.2801 MeV maximum energy, 0.9336 MeV 
average energy. The maximum and mean energy are of 90Y. 
10523 days 
106Ru/106Rh Beta emitter, 3.541 MeV maximum energy, 1.41 MeV average 
energy. The maximum and mean energy are of 106Rh. 
373.59 days 
 
Table 1. Isotopes that have been or are currently used for eye plaque radiation therapy. The average 
energies are nominal values assuming typical encapsulation of the sources. 
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While a number of authors have reported the use of 60Co14, 18, 32-34 or 192Ir14, 35 eye plaques, both 
have major disadvantages. Because of their relatively high photon energy (and thus deep 
penetration), achieving dose conformity over the small distances associated with ocular tumors 
presents a challenge, in addition to the unavoidable radiation protection issues.  By contrast, the 
depth-dose distribution of 125I is similar to those of 60Co and 192Ir within the first 15 mm, but 
attenuates rapidly beyond this depth35-37. Reducing the dose from 60Co by 50% requires a 12 mm 
lead shield, while only 0.5 mm of gold decreases the dose from 125I to less than 0.1%37. This 
effectively protects the structures posterior and lateral to the plaque, and prevents the medical team 
from receiving an unnecessary dose. Therefore, 125I has become the radionuclide of choice for the 
Collaborative Ocular Melanoma Study (COMS), a large international controlled study initiated in 
1986 and supported by the National Eye Institute37. Since this selection was made, 125I has been 
the most widely used isotope for eye plaques in the U.S. The design of the COMS study eye 
plaques has been standardized37, 38, and has become the most widely used eye plaque geometry in 
the U.S. as well as the geometry of choice in many institutions outside the U.S. Their design has 
been described in detail31, 39, 40.  
In Europe, eye plaque therapy has primarily utilized 106Ru eye plaques since their invention by Dr. 
Lommatzsch in 19645, 6. A beta-emitter with a maximum energy of 3.541 MeV and a half-life of 
373.59 days41, 106Ru/106Rh provides more conformal dose distributions than 125I due to its rapid 
dose fall-off and offers better protection to critical structures of the eye, but is limited to tumors 
not higher than 5 mm6, 7. Treating larger tumors with 106Ru eye plaques would result either in 
underdosing the tumor, or in an unacceptably high scleral dose and unacceptably long treatment 
time. All 106Ru eye plaques are manufactured by Eckert & Ziegler BEBIG GmbH, Berlin, 
Germany. This company took over the former East German entity that had manufactured the 
 4 
 
plaques since their invention.  106Ru eye plaques have never been widely used in the U.S., likely 
because they were originally manufactured in the German Democratic Republic, and meanwhile 
the U.S. adopted the COMS plaques. The COMS plaques have no tumor height restriction, a 
limitation on the use of 106Ru eye plaques when dose delivery to the apex of the tumor is judged 
to be optimal and is prescribed accordingly. In Europe, ophthalmologists often follow a different 
prescription philosophy that prioritizes delivery of a proper dose to the tumor base over tumor apex 
dose, thereby eliminating the 5 mm limitation on tumor height (private communication). 
Moreover, 106Ru eye plaques had to be commissioned dosimetrically, and were plagued by 
erroneous dosimetric data and non-uniform dose distributions, which are subjects of this work and 
described in the published article42. It should also be noted that between 2007 and 2011, the 
manufacturer of 106Ru eye plaques, stopped deliveries to the U.S. for business reasons (private 
communication). Furthermore, while the user can control the dose rate of COMS plaques by 
ordering seeds of appropriate strength, thereby enabling insertion and removal of the eye plaques 
at convenient times, the dose rate of 106Ru eye plaques is a given on the specific dates of the 
procedures, causing operating rooms scheduling issues (private communication). 
In the COMS study, which dealt with choroidal melanomas, the choice of optimal treatment 
decision between enucleation or radiation therapy was concerned with preservation of vision or 
cosmetic appearance as well as with patient survival8, 9, 43. It was hypothesized that enucleation 
may disseminate micrometastasis and thus result in metastatic disease, a situation presumably 
avoided with radiation therapy43. Therefore, the main question for the COMS study 
ophthalmologists was which treatment is superior in terms of extending the patient’s life43. The 
outcome of the COMS study8, 9, which was published in 2001-2002, found “the absence of a 
clinically or statistically significant difference in survival for patients randomly assigned to 
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enucleation versus brachytherapy” and that local treatment failures after plaque therapy were 
“relatively infrequent events.” Confirmed mortality rates from metastatic melanoma at 5 years 
were 9% after plaque therapy and 11% after enucleation8. In the case of 106Ru, Seregard11 re-
analyzed results of plaque therapy for melanoma from 5 trials. He reported a 6% melanoma 
mortality rate at 5 years and concluded that the survival rate appears higher after plaque therapy 
than after enucleation. For retinoblastoma it was shown16, 19, 44 that eye plaque therapy provides a 
rate of local control as high as 89% at 52 months of follow-up. 
1.1. COMS eye plaques. 
COMS plaques consist of a 0.5 mm thick gold alloy (Modulay) backing and a silicone insert with 
5 mm long x 1.25 mm deep grooves for the loading of standard brachytherapy seeds, which are 
approximately 4.5 mm long x 0.8 mm in diameter. The gold alloy backing serves as a holder for 
the silicone seed carrier insert, and has 6 tabs with suture holes, but its main purpose is radiation 
shielding. The rounded metal backing is surrounded by a cylindrical part called the “lip” that is 
designed to protect such sensitive structures as the optic nerve, optic disk, and macula. The seed 
carrier insert is made of medical grade silicone rubber (Silastic). The radius of its internal curvature 
is 12.3 mm conforming to 24.6 mm, which is considered the “average” diameter of an eye. It has 
fixed locations for the seeds, and it assures that all seeds are at 1 mm distance from the outer scleral 
surface. The 1 mm distance is required in order to minimize “hot spots” in the scleral layer31, and 
was originally intended to achieve a dose distribution approximating that of the commercially 
available pre-COMS 60Co plaques37. 
A number of alternative plaque designs employing 125I brachytherapy seeds have been in use since 
the 1980s35, 36, 44-51. Some designs also utilize 103Pd brachytherapy seeds20, 26, 51, even though the 
first experiments with 103Pd seeds used the COMS design52. Calculations for the use of 103Pd in a 
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COMS plaque design are described by Chiu-Tsao et al40, but it is not clear if this configuration 
was ever used clinically, except as reported by Finger52. 
There are, however, a number of problems related to the use of COMS eye plaques. The COMS 
plaques are 2.75 mm thick39, causing patient discomfort. Dosimetrically, the COMS plaques have 
localized hot and cold spots, since they are assembled from separate brachytherapy seeds. The 125I 
seeds in COMS plaques are arranged in a standard geometry. The dosimetry of the seeds is 
assumed to be described by the TG-43 formalism53. Treatment planning calculations assume the 
point source model for the seeds, and assume that the seeds are surrounded by homogenous liquid 
water. The latter assumption ignores the effects of the gold alloy backing, the Silastic insert, inter-
seed attenuation, eye-air interface, and other possible factors that could affect the low energy 
photon scatter54. Several authors have attempted to calculate and/or measure these effects55-58, but 
they either measured the effect of a plaque loaded with a single seed55-57 or focused on the effects 
outside the shielding lip58. These works suggest a dose reduction in the range of 10% or more at 1 
cm from the seed along the central axis of the plaque as compared to homogenous water. Recent 
assessments and Monte Carlo simulations54, 59, 60 including fully loaded plaques found that the 
delivered dose is substantially lower than the accepted point source model in homogenous liquid 
water. Some of these measurements and calculations were done in full scatter phantoms and some 
were made in phantoms mimicking the human head with an eye to air interface. Phantom selection 
affected the results. Monte Carlo simulations by Thomson et al54 in a full scatter phantom found a 
14% dose reduction 1 cm from the inner sclera along the central axis of the plaque for a 20 mm 
COMS plaque fully loaded with 125I seeds.  Our measurements of a fully loaded 20 mm COMS 
plaque performed using radiochromic film in the Solid Water “eye” phantom placed into a full 
scatter phantom confirmed the Monte Carlo results by Thomson et al54 and the corrected Plaque 
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Simulator results, the only commercially available eye plaques treatment planning software. These 
are presented in this work and were also reported at an Annual Meeting of the American 
Association of Physicists in Medicine (AAPM)61, earning the Best in Physics award. These 
measurements were done at the request of Dr. Chiu-Tsao, Chair of the AAPM’s Task Group 12940, 
who was impressed by our earlier dosimetry of 106Ru eye plaques and wanted to experimentally 
confirm the Monte Carlo simulations of 125I COMS eye plaques by other groups, as well as to test 
the dosimetric corrections by the author of Plaque Simulator59, 62-64. These measurements were 
necessary because Monte Carlo simulations can be trusted only if verified by experiment. Unlike 
earlier reports55-58, for the first time, this work presents a complete experimental characterization 
of a fully loaded COMS plaque. 
1.2. 106Ru eye plaques. 
The 106Ru eye plaques are made of pure silver (Ag 99.99%) with a total thickness of 1 mm. The 
shape is a spherical cap with an inner radius of 12 to 14 mm, which conforms to the typical human 
eye65. The radioactive material, 106Ru/ 106Rh in the form of a thin film, is electrolytically deposited 
on 0.2 mm-thick silver foil that is encapsulated between a 0.1 mm silver window on the concave 
(facing the eye) side and the silver backing that stops approximately 95% of the beta-radiation 
posterior to the plaque41.  
Since 106Ru eye plaques are made of a continuous layer of encapsulated radioactive material, all 
treatment planning calculations are based on actually measured dosimetric data for each eye 
plaque. These data are provided by the manufacturer in the form of absolute dose rate measured 
as a function of depth (distance from the inner concave surface of the plaque along its central axis). 
The manufacturer also provides a surface map of dose rates relative to that on the central axis at a 
specified number of points, measured on concentric circles around the central axis 1 mm from the 
 8 
 
plaque’s surface. Prior to 2002, dosimetric data was provided by BEBIG for only 4 points along 
the central axis and 9 surface points on a circle for small plaques or 17 surface points on 2 circles 
for the larger plaques (see an example of a small plaque certificate in Appendix 2). The surface 
points were and still are measured 1 mm from the plaque’s inner surface. The cylindrical (see 
below) detector long axis is parallel to the central axis of the plaque, which means that it is 
perpendicular to the plaque’s surface only on the central axis of the plaque and is angled relative 
to the surface at all other points (personal observation during a visit to the plaques manufacturer 
BEBIG). Therefore, these measurements are of questionable value. At that time the dosimetric 
data had a stated uncertainty of ±30% (k=2). The manufacturer data were acquired with a 
cylindrical plastic scintillator (2 mm height by 2 mm diameter) with the absolute absorbed dose 
rate calibration based on the primary standard of the national laboratory of the former German 
Democratic Republic. The large detector lacked the necessary resolution needed to measure the 
rapidly changing dose distributions of the small concave plaques with dose gradients as large as 
30%/mm. A number of authors66-74 have attempted to reduce this uncertainty and to perform 
quality assurance of the plaques. The findings included dose rate disagreements between -37% to 
+74% with the manufacturer’s data72 and non-uniform dose distributions with off-axis hot and 
cold spots. These results are discussed in more detail in our published article42. Our own 
measurements using radiochromic film in our specially designed Solid Water “eye” phantom and 
with a small semiconductor diode in a water tank found that dose rates provided by the 
manufacturer were 1.55 – 2.11 times lower than our findings, with off-axis hot spots of up to 
23%42, 75-77. The diameter of the mechanically smallest (CCX type) plaque is 11.6 mm, and its 
internal height is just 1.3 mm. Due to its small size this plaque is ideally suited for the treatment 
of retinoblastoma in small children as young as one week old. The CCX plaques are notoriously 
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difficult to measure due to their small size and therefore, until recently, except for our published 
data of the CCX 41 plaque78, there was no published dosimetric data for these plaques79. Our data78 
was used by Hermida-López79 for comparison with his Monte Carlo simulations. Our published 
article42 and this work include additional data on CCX plaques. Hermida-López recently published 
his measurements of two CCX plaques as well80. 
Prior to the 2002 NIST (U.S. National Institute of Standards and Technology, Gaithersburg, MD) 
calibration, CCX plaques had the highest dosimetric discrepancy between BEBIG’s dosimetry and 
the improved dosimetry done by NIST81. The central axis dose rate disagreements were assumed 
to result from the large size of the plastic scintillator detector employed by BEBIG, as well as its 
calibration for absolute beta dosimetry. The non-uniform dose distributions were attributed to the 
non-uniform distribution of the radioactive isotope under the surface of the plaque. In May of 
2002, BEBIG sent a letter to its customers81 informing them that the company had started using a 
smaller plastic scintillator (1.0 mm diameter and 0.5 mm height) calibrated by the NIST, which 
reduced the uncertainty to ±20% (k=2). They also started providing dosimetric data at 11 points 
along the central axis and 33 off-axis surface points (see an example of a small post-2002 plaque 
certificate in Appendix 3). In the same letter81, BEBIG provided conversion factors from the old 
ASMW (standardization office of the former German Democratic Republic) dosimetry to the NIST 
calibrated dosimetry, which are in close agreement with our results for the plaques measured in 
this work42. BEBIG also improved their manufacturing processes, resulting in more uniform dose 
distributions. The improvements in accuracy of the dosimetric measurements and the better 
uniformity of the dose distributions were verified by our independent measurements42, 82, 83. 
106Ru eye plaques provide a convenient and good alternative to COMS 125I plaques in treating 
small intra-ocular malignancies. They are substantially thinner than the COMS plaques (1 mm vs. 
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2.75 mm), and are much better tolerated by patients, do not require assembly, can be reused, and 
offer more conformal dose distributions than 125I eye plaques due to a more rapid dose fall-off. A 
recent publication84 reported findings of a FMEA (failure mode and effects analysis) of the COMS 
plaque process in accordance with the TG-100 AAPM report85. The publication84 found that the 
COMS plaques technique consists of 12 major processes, 121 sub-processes and 188 potential 
failure modes, starting with the diagnosis and ending with the treatment. At least 50 of the 188 
potential failure modes are a consequence of the fact that COMS plaques are assembled from 
individual seeds; these failure modes are eliminated by the use of 106Ru eye plaques.  
There are also, however, a number of problems related to 106Ru eye plaques. The local control rate 
in radiation therapy strongly depends on the delivery of a certain minimal dose to the tumor, while 
the overall clinical result in terms of preserving vision or the eye (for cosmetic reasons) – is a 
function of keeping the doses to critical structures of the eye at an acceptable level. Messmer et 
al86 report that a decrease in external beam radiation dose used for the primary treatment of 
retinoblastoma from 50 Gy to 40 Gy increased local failures observed within 26 months after 
radiation therapy from 22% to 49%. Hermann et al87 compare the outcomes of various studies and 
conclude that for melanomas treated with 106Ru plaques, there is no significant difference in 
treatment outcome when the apical dose (the usual prescription point in the treatment of 
ophthalmic tumors) is increased from 100 Gy to 160 Gy. The authors87 suggest defining a system 
that can characterize the dose distribution in the tumor as a basis for comparison among studies, 
because it seems that the apical and basal doses alone are insufficient for this purpose. But 
Hermann et al87 overlooked the possibility that the various studies use either incorrect or 
incomparable dosimetric data. We hypothesize that the very large uncertainties associated with the 
manufacturer’s dosimetry can explain the discrepancy between various published studies. 
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 An additional source of failures of 106Ru plaques is insufficient coverage close to the rim of the 
plaque. Taccini et al71 found a dose rate decrease to less than 40% of the uniform value in the 
region 1 mm from the rim of the plaque, which is farther from the rim than expected based on 
BEBIG’s earlier specifications of a 0.60 mm – 0.75 mm inactive area for most of the plaques. 
BEBIG’s most recent specification30 defines an inactive border 0.75 mm from the rim for most of 
the plaques. Our work42 confirms that for one of the measured CCX eye plaques the uniform 
coverage ended 1.25 mm from the rim vs. the expected 0.75 mm. This insufficient coverage close 
to the rim of the plaques may explain findings by Barker et al88 of higher than anticipated numbers 
of tumor recurrences when using 106Ru eye plaques.  Barker et al88 suggested adding 3 mm wide 
margins to the tumor size when selecting a plaque in order to achieve sufficient tumor coverage. 
Another dosimetric issue of importance concerning 106Ru plaques are dose distributions in plaques 
with cutouts. The manufacturer provides a standard set of measured data which includes the dose 
rate on the central axis and the relative surface dose rates measured at 33 points at a distance 1.0 
mm from the inner concave surface. These data, however, neither show nor suggest that the dose 
on the central axis is not the highest dose in the planes perpendicular to the central axis (see an 
example of a plaque certificate with a cutout in Appendix 4). These plaques apparently contain 
substantial hot areas shifted with respect to the central axis, as seen from our measurements of a 
CIA plaque with a cutout presented in this work and in the published article42. Since the dose is 
prescribed along the central axis of the plaque, the off-axis hot area overdoses a part of the eye. 
This must be made known to the prescribing physician and taken into account whenever relevant. 
 Recent published guidelines from AAPM and GEC-ESTRO state that 106Ru plaques must be 
commissioned dosimetrically by a medical physicist prior to clinical use89. This requirement is in 
line with the requirements of the AAPM’s TG-40 Report90, which includes acceptance and quality 
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assurance requirements of brachytherapy sources.  At present, there are no 106Ru primary 
calibration standards in the U.S. and most other countries, and therefore there is no ADCL 
(Accredited Dosimetry Calibration Laboratory) calibration available and commercial tools or 
instruments for the acceptance and commissioning of 106Ru eye plaques are unavailable. This 
deficiency is addressed by the findings in this thesis. 
The thesis evaluated dosimetrically 8 different 106Ru eye plaques belonging to CCX, CCA and 
CIA types.  
Absolute dose values can be measured in a precise way by a qualified medical physicist during the 
commissioning of the eye plaque using methods described herein as well as other techniques41. 
However, the dose non-uniformity, including the region close to the rim of the plaque, can hardly 
be accounted for by current one-dimensional treatment planning techniques. This can result either 
in the underdosing of the tumor or the overdosing of adjacent healthy eye tissue, contributing to 
treatment complications and side effects. Our published article42 describes a two-dimensional 
treatment planning technique, developed at Memorial Sloan-Kettering Cancer Center (MSKCC) 
with our participation - that uses the eye plaques dosimetric data measured in this work and that 
can account for dose non-uniformities of the actual plaques. 
1.3. Novel 125I eye plaque. 
To overcome the above limitations and technical difficulties associated with 125I and 106Ru eye 
plaques, Implant Sciences Corporation of Wakefield, MA developed a prototype novel 125I eye 
plaque design using ion implantation techniques. In contrast to 125I plaques assembled from 
brachytherapy seeds, the novel design creates a continuous layer of 125I in a glass substrate within 
the plaque. The plaques are approximately 1 mm thick (similar to 106Ru plaques). It was 
hypothesized that the ion implantation technique could create a plaque with very uniform 125I 
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density, which would result in highly uniform dose distributions without the hot or cold spots 
typical of plaques assembled from brachytherapy seeds or the dosimetric non-uniformities seen in 
106Ru eye plaques. Since 125I isotope is utilized, the plaque would not be limited to treating tumors 
with apical heights of 5 mm or less. However, these plaques would have to be commissioned 
dosimetrically by measurements, like 106Ru eye plaques. Dosimetry of 125I photons introduced 
additional challenges addressed by this thesis. 
The ion implantation technique and equipment used in this project were developed by Implant 
Sciences Corporation in order to manufacture 125I brachytherapy seeds. Accelerated 124Xe ions 
bombard a silicon dioxide (quartz) target, penetrating its surface. To manufacture an eye plaque, 
the target, which is a segment of a hollow sphere of quartz, is moved uniformly through the ion 
beam. The expected result is a relatively uniform slightly subsurface distribution of 124Xe ions. 
The quartz substrate is then encapsulated in a thin layer of titanium (100 µm – 200 µm) and 
activated by neutron irradiation in a nuclear reactor, creating a relatively uniform, slightly 
subsurface distribution of 125I. The activated plaque would be attached to a gold backing with 
suture eyelets similarly to COMS plaques. After using the plaque on a patient, the decayed plaque 
could be re-activated in a nuclear reactor and reused for other patients, since only a small fraction 
of 124Xe would become 125I during each activation. The re-activation of used plaques could 
potentially reduce costs, allowing the company and hospitals to keep sufficient numbers of plaques 
on hand given the substantially shorter 59.43 days53 half-life of 125I as compared to the 373.59 
days41 half-life of 106Ru.  
Implant Sciences Corporation has additionally proposed the creation of a special collimator insert 
covering the inner (concave) surface of the plaque. This collimator would be custom manufactured 
for each patient using a 3D conformal treatment plan based on 3D imaging information of the 
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diseased eye, enabling simultaneous delivery of radiation from multiple directions, similar to non-
coplanar external beam radiation treatments. The collimator would be made of gold in the shape 
of a 0.13 mm thick spherical cap with groups of 0.1 mm diameter holes spaced 0.13 mm apart in 
a hexagonal array. Each group would correspond to a “radiation beam”, such that all beams would 
result in a 3D conformal dose distribution covering the tumor and sparing the critical structures of 
the eye. The collimator would precisely fit the inner concave surface of the eye plaque. This 
approach will likely reduce the number of complications and toxicities of eye plaque 
brachytherapy reported by many authors5, 6,12-15, 17, 20, 22, 25-27, 45, 91-95, which may result in loss of 
vision and enucleations. 
This work reports dosimetric measurements performed on two 16 mm diameter prototype 125I eye 
plaques made by Implant Sciences Corporation using radiochromic film in our Solid Water “eye” 
phantom and a small semiconductor diode in a water tank, based on methodology that was 
successfully applied by the author for accurate beta dosimetry of 106Ru eye plaques.   
The first prototype was not a final design eye plaque, but was used in order to study the feasibility 
of achieving dose uniformity as well as a clinically useful dose rate in the range of 60 cGy/hour – 
105 cGy/hour at the tumor apex as recommended by the American Brachytherapy Society96. The 
second prototype was a fully assembled eye plaque, which, except for suture lugs, included all 
parts of the final product including a prototype collimator. We report full dosimetric 
characterization of the second prototype eye plaque using radiochromic film in our Solid Water 
“eye” phantom without the collimator and a comparison of the measured results with Monte Carlo 
simulations. We further report testing the feasibility of the collimator, studying possible dose non-
uniformity resulting from the collimator design, as well as the clinical usefulness of the resulting 
dose rate, since the collimator would significantly attenuate the dose rate of the eye plaque. 
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Dosimetry of the novel125I plaques presented further challenges, since radiochromic films have 
always had strong energy dependence at low photon energies97-100. This energy dependence has 
improved starting with the new EBT film101, 102. The strong energy dependence of the older types 
of film that use the GAFCHROMIC film emulsion and the lesser dependence of the newer types 
that use the EBT emulsion have been shown by Monte Carlo simulations103, but this remains an 
unresolved issue. It appears that the energy dependence at the low photon energies strongly 
depends on certain chemicals in the active layer and is film batch dependent104, 105. Therefore, the 
low energy of the 125I eye plaque photons made it impossible to use high energy linac or 60Co 
beams for radiochromic film calibration purposes, as was done for 106Ru eye plaque measurements. 
Consequently, calibration of films for measurements at 125I energy requires a source of the same 
energy. A unique film calibration method using a 125I seed in our Solid Water “eye” phantom was 
developed in this work. Measurements at low photon energies required placements of the 
phantoms for eye plaque dosimetry or seed calibration into an appropriate scatter phantom, since 
the contribution of photon scatter to the absorbed dose could be as high as 38%106. The dosimetry 
of the novel 125I eye plaque was also done using a semiconductor diode. While semiconductor 
diodes were used for absolute dosimetry of 106Ru eye plaques42, 67, to the best of our knowledge 
diodes were previously used only for relative dosimetry of 125I brachytherapy seeds107-109 and 125I 
eye plaques110. In this work the semiconductor diode was calibrated for absolute dosimetry of 125I 
using a calibrated 125I brachytherapy seed. 
1.4. Radiochromic film. 
Radiochromic film is the main tool used for eye plaque dosimetry in this work. Radiochromic film 
is a color monochrome film that, produces an image as a result of irradiation, without any kind of 
chemical or non-chemical (for example thermal) processing and is almost insensitive to visible 
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light111, 112. All radiochromic films used in this work were GAFCHROMIC™ films developed, 
manufactured and provided by International Specialty Products (ISP, Wayne, NJ). In 2011 ISP 
was acquired by Ashland (Covington, KY). Currently, they are the sole manufacturer of 
radiochromic film in the sensitivity range reasonable for use in the field of medical dosimetry. 
In 1998, the AAPM Task Group 55 (TG-55)98 published recommendations for film dosimetry 
using radiochromic film98. Many new types of film, however, have been developed since 1998. In 
addition, conventional radiographic film is no longer being manufactured and its use has been 
replaced by radiochromic film and/or digital devices. A review co-authored by the author updated 
the status of radiochromic film, covering all film types up to and including EBT film released in 
2004113. Since then, as part of ongoing research and development, ISP changed technology and 
moved to EBT2 and then EBT3 films. The AAPM therefore formed a new Task Group 235 for the 
purpose of updating the original TG-5598. The author is a member of TG-235, and certain results 
of this work are included and cited in the TG-235 report, which is currently undergoing final 
review prior to publication114.  
A few important features of radiochromic film: 
• The film is sensitive to polarization of the readout light source. Therefore, directions of 
cutting and scanning should be strictly controlled. This variation can be as large as 80%115 
depending on the film scanner used. Rotating the film by 90 degrees can result in variation of 30% 
in measured optical density using our Epson 1680 scanner. 
• The pre-EBT types of radiochromic film, such as MD-55-2, were inherently non-
uniform116, 117. The non-uniformity was mainly caused by thickness variation of the sensitive layer 
of the film and was about 4% in the direction of coating vs. 15% in the perpendicular direction. 
The direction of coating was marked by the manufacturer on each sheet of film. The sheet size of 
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MD-55-2 film was only 12.5 cm x 12.5 cm (5” x 5”). In accordance with our method of managing 
film non-uniformity, all sheets of film belonging to a specific production lot were cut into 3 cm-
wide strips in the direction of coating using a precise office paper cutter, keeping track of each 
strip’s position on the sheet (for example ─ first strip from the left). Films used for measurements 
of a particular eye plaque would always belong to the same strip, continuing from sheet to sheet. 
This produces sub-film lots with an inherent non-uniformity in the 4% range, rather than the 
possible 15% if films were randomly cut from any location on the sheet. We applied this technique 
for dosimetric measurements of CCX 41 and CCX 55 eye plaques using MD-55-2 film, as well as 
the first prototype of the novel 125I eye plaque using XR-T film. 
Starting with EBT film the production processes achieved greater control over the thickness of the 
active layer, substantially improving the uniformity of the film. The later EBT2 and EBT3 films 
employ a different chemistry and coating technology, and include a blue dye component in the 
active layer that, is almost insensitive to radiation. This makes it possible to further account for 
thickness variation of the active layer, thereby improving film dosimetry precision by applying 
multi-channel dosimetry techniques118. 
• The other major deficiency of pre-EBT radiochromic film was its low sensitivity. Due to 
the low sensitivity the dosimetric characterization of a 106Ru eye plaque could take over a month, 
comprising a significant part of the source’s one year useful life. The extended exposure times can 
also potentially affect the measurement uncertainty due to possible dose rate effects119. 
• Radiochromic film has inherent post-exposure growth of optical density which we found 
was 16% in the first hour after irradiation, but substantially lower after a few hours. Therefore, the 




Despite the issues detailed above, radiochromic film is almost an ideal dosimeter for eye plaque 
dosimetry as well as any other dosimetric application in radiation therapy due to its near tissue 
equivalency (except for XR-T film) and sub-millimeter spatial resolution. On the other hand, due 
to the noted sensitivity to polarization, inherent non-uniformity, post-exposure growth, and some 
additional environmental dependencies, such as temperature and humidity, absolute dosimetry 
using radiochromic film requires following a rather strict protocol, as described in the literature73, 
98, 111-113, 116, 117, 119-122, learned through trial-and-error and additionally refined in the process of this 
work. 
While working on dosimetry of 106Ru eye plaques the author proposed to the manufacturer of the 
film the idea of developing a new type of radiochromic film that would provide substantially higher 
sensitivity and uniformity than the present films. Increasing the sensitivity by about 15 times 
(which would require about 200 cGy for an optical density of 0.5) and significantly improving the 
uniformity would result in a film that can replace radiographic film in many mainstream 
applications such as IMRT and linac QA, which have much larger markets than brachytherapy 
dosimetry, providing the company with an incentive to invest in the project. To accomplish this 
objective, the manufacturer would also have to supply film in large sheets (at least 8 in x 10 in vs. 
the then current 5 in x 5 in) and bring the price of the film into a range comparable with 
radiographic film (from $50 for a 5” x 5” sheet to $10 for an 8” x 10” sheet). After rigorous 
marketing studies with participation of the author, the manufacturer agreed to proceed with 
development of a new type of radiochromic film, which was commercially released in 2004 under 
the name EBT film. In the course of the development of the new film the author was the first to 
test samples of the new batches, and to uncover new problems. One key discovery was the finding 
of significant non-uniformity, which was not expected. The investigation of the possible causes 
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led to the discovery of a very strong dependence of the new active component on environmental 
humidity. Eventually, this was significantly improved by changes to the film chemistry and to the 
packaging of the films, which to this day are packaged with paper sheets interlaced between the 
sheets of film. While the moisture effect on film non-uniformity was substantially improved, 
environmental moisture in the film still had a strong effect on dosimetry results. The author further 
investigated this issue and worked out a solution involving cutting the film at least 24 hours prior 
to irradiation, enabling its moisture content to equilibrate with the environment42, 113. As the author 
found, the moisture did not actually affect the dose measured by the film, but instead affected the 
scanned optical density up to 10% in the absence of a 24 hour period to equilibrate with the 
environment. Our recommendation was not only suggested in Soares et al113, but was also 
incorporated into the forthcoming TG-235114. Another problem identified by the author was the 
lateral scanner artifact, later studied by many researchers115, 123-129. Some of our early EBT 
experience was presented at an AAPM annual meeting130. Following the development of EBT 
film, the author of this work was the first to test prototype EBT2 films, and first to test and use 
special unlaminated EBT1, EBT2 and EBT3 films. 
1.5. Monte Carlo simulations. 
Dosimetric results in radiation therapy are usually reported in terms of dose to water53, 131, while 
dosimetric measurements are frequently done in “water equivalent” solid phantoms that enable 
precise measurement setups, such as the eye plaque dosimetry reported in this work. Several 
authors have reported that Monte Carlo simulations are a good tool for conversion between dose 
to media and dose to water132-135. All film dosimetry in this work was done in Gammex 457 Solid 
Water™ (Gammex, Middleton, WI, Sun Nuclear Corporation) water-equivalent plastic. Meigooni 
et al135 report that there are two main types of Solid Water with either a 2.3% or 1.7% calcium 
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content. This difference can affect the conversion factors for 125I by as much as 5%. A sample of 
Solid Water used in this work was sent to a chemical laboratory for calcium content testing. We 
initiated additional Monte Carlo simulations in order to study conversion between dose to film in 
Solid Water and dose to liquid water, since Meigooni et al135 did not examine film in Solid Water, 
but only reported Solid Water conversions to liquid water. We report Monte Carlo derived 
conversion factors from Solid Water to liquid water for 125I dosimetry and their dependence on 
radiochromic film type, as well as on the calcium content of Solid Water. 
2. Materials and Methods. 
2.1 Eye plaques. 
2.1.1 106Ru eye plaques. 
Eight different 106Ru eye plaques belonging to three types (CCX, CCA and CIA) were 
dosimetrically characterized in this work. Front and back views of several 106Ru eye plaques are 
shown in Figure 2. The CIA plaque in Figure 2 has a cutout in order to position it in the vicinity 
of the iris30. A typical cross section of a 106Ru plaque is shown in Figure 3, and all 16 types of 
106Ru eye plaques manufactured by Eckert & Ziegler BEBIG are shown in Figure 4. 
The plaques are made of pure silver (Ag 99.99) with a total thickness of 1 mm. The shape is a 
section of a hemisphere with an inner radius of 12 to 14 mm, which conforms to the typical human 
eye dimension65. Each eye plaque has several suture lugs used to suture it to the sclera. 
The radioactive material, 106Ru /106Rh in the form of a thin, electrolytically deposited layer on a 
0.2 mm thick silver foil is encapsulated between a 0.1 mm silver window on the concave (facing 
the eye) side, and 0.7 mm thick silver backing which stops approximately 95% of the beta-radiation 








Figure 2. Front and back views of a CCA, CIA, and CCX eye plaques. These are “dummy” 
plaques, which are an exact silver replica of the appropriate plaque, but without the radioactive 






Figure 3. Cross section of a 106Ru eye plaque (reprinted from an eye plaque data sheet by 




Figure 4. All 16 types of 106Ru eye plaques manufactured by Eckert & Ziegler BEBIG (reprinted 
from User Manual: Ru-106 Eye Applicators Rev. 1230 by permission from Eckert & Ziegler 
BEBIG). 
The 106Ru /106Rh mother-daughter system emits beta-radiation with a maximum energy of 3.541 
MeV, as well as 20% 0.512 MeV, 10% 0.622 MeV, 1.6% 1.05 MeV, 0.4% 1.13 MeV, and 0.2% 
1.55 MeV gamma radiation per decay41. Bremsstrahlung produced by interactions of the beta 
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particles with the source material is also emitted41. The half-life of the parent isotope is 373.59 
days41.  
The first plaque characterized was CCX 36. The dosimetric measurements of this plaque were 
done using the NIST phantom provided to us by Dr. Soares (NIST) and shown in Figure 14. The 
remaining seven plaques: CCX 41, CCX 55, CCX 104, CCX 129, CCX 219, CCA 892, and CIA 
156 were characterized using a Solid Water “eye” phantom designed in the course of this work 
(the number after the plaque type is the serial number of the plaque). The CCX plaques have a 
diameter of 11.6 mm and internal height of 1.3 mm and are mechanically the smallest plaques 
manufactured by BEBIG. They were of special interest at Memorial Sloan-Kettering Cancer 
Center for treatment of retinoblastoma in small children and therefore 6 out of the 8 plaques belong 
to this type. CCA has a diameter of 15.3 mm and internal height of 2.3 mm. CIA has the same 
dimensions as CCA, but has a cutout for treatment of ciliary body melanoma30.  
2.1.2 COMS plaques. 
The design of COMS plaques was standardized for the COMS study37, 38. 
All COMS plaques in the U.S. and originally for worldwide use are manufactured by Trachsel 
Dental Studio, Inc. in Rochester, MN. Chiu-Tsao31 describes the design of the standard COMS 
plaques, which have been made in 5 diameters of 12 mm, 14 mm, 16 mm, 18 mm, and 20 mm. 
Chiu-Tsao31 also provides the exact seed arrangement for every plaque and the material 
composition of the gold backing. An unpublished document by Kline136 provided by Trachsel as a 
data sheet/user manual describes exact details of the design, drawings and material compositions 
including plaques with cutouts. Later publications by Chiu-Tsao et al39, 40 add two additional 
diameters of eye plaques to the original five – 10 mm and 22 mm, which were not included in the 
study, but eventually were made available by Trachsel.  
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A typical design of a COMS 125I eye plaque is shown in Figure 5 below, while its components are 
shown in Figure 6. 
 
 
Figure 5. Cooperative Ocular Melanoma Study plaque design (reprinted from Chiu-Tsao39). 
 
The gold alloy backing is made of an approximately 0.5 mm thick alloy with a trade name 
Modulay, which consists by weight of 77% gold, 14% silver, 8% copper, and 1% palladium39, 40, 
136. The alloy was selected for its biological inertness, ease of fabrication and shielding 
properties136. The gold alloy backing holds the Silastic seed carrier insert, which is glued to its 
internal concave surface. The backing serves as a radiation shield and stops approximately 99% of 
the radiation37. A cylindrical part called the “lip” surrounds the rounded backing. The “lip” is 
designed to protect sensitive structures as the optic nerve, the optic disk, and macula. The “lip” 
has six lugs with suture holes enabling suturing the plaque to the sclera. The seed carrier insert is 
made of medical grade silicone rubber called Silastic (Dow Corning Corporation, Midland, MI) 





Figure 6. COMS plaques: gold backings, silastic inserts, assembled plaques without seeds. 
 
The radius of the seed carrier’s internal curvature is 12.3 mm conforming to 24.6 mm, the 
“average” diameter of the human eye. It has fixed locations for the seeds, and it assures that all 
seeds are at 1 mm distance from the outer scleral surface. AAPM’s TG-12940 provides the seed 
locations for all seven COMS plaques shown in Figure 7 and a table of seed coordinates for each 
plaque. The seed coordinates can be used in standard treatment planning systems, like Pinnacle 
(Phillips North America Corporation, Andover, MA) and Eclipse BrachyVision (Varian Medical 
Systems, Inc., Palo Alto, CA) in conjunction with TG-4353, 137, enabling treatment planning 
calculations of COMS eye plaques. Unfortunately, these widely used approaches do not correct 
for the combined dose reduction effects of the gold alloy backing, Silastic seed carrier and other 




Figure 7. Seed diagrams for 10 mm – 22 mm COMS plaques viewed from the internal (concave) 
aspect of the seed carrier insert (reprinted from Chiu-Tsao et al40). 
 
The 20 mm COMS plaque studied in this work was assembled from standard Modulay backing 
and Silastic seed carrier (Trachsel Dental Studio, Inc. Rochester, MN) used for treatment of 
patients at Memorial Sloan-Kettering Cancer Center (MSKCC). One complication in building the 
phantom parts was the discovery that the Modulay backing was not perfectly round with its 
diameter varying from 20.66 mm to 21.20 mm, so we used the average of several measurements 
around the plaque of 20.80 mm. Also, its thickness varied between 0.48 mm and 0.51 mm, as one 
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could probably expect from a product manufactured by a dental workshop. A picture of the 
concave side of the fully loaded 20 mm plaque is shown in Figure 8. 
 
 
Figure 8. Picture of the fully loaded 20 mm COMS eye plaque dosimetrically characterized in 
this work. The Oncura 6711 seeds are visible through the silicone seed carrier. The ruler in the 




The plaque was loaded with 24 Oncura Model 6711 125I seeds with air kerma strength 6.75 U/seed 
on the reference date (apparent activity 8.57 mCi/seed) provided for this work by Oncura, Inc. 
(Arlington Heights, IL). The seeds were requested to have air kerma strengths within 1% of each 
other. The reported average of the batch was 6.7517 U with 0.0211 U standard deviation. The 
highest deviation of a single seed from the average was 0.60%. After receipt of the seeds they were 
calibrated using an HDR 1000 Plus S/N A990685 well chamber with the seed insert calibrated by 
the University of Wisconsin ADCL for the 6711 seed with a calibration coefficient 0.2376 U/pA 
and the Standard Imaging Max 4000 S/N E041325 ADCL calibrated electrometer with calibration 
coefficient 1.000. The calibration results had an average of 6.7023 U, with standard deviation of 
0.0267 U on the same reference date as that specified by the manufacturer. The calibrated average 
differed only -0.73% from the reported average air kerma strength of the batch, which is excellent 
agreement. The highest deviation of a single seed calibrated by us from the batch average was 
0.8%. The manufacturer’s air kerma strength was used for further calculations. 
2.1.3 Novel 125I eye plaque and collimator. 
The drawings of the cross-sections and bottom views of the two 16 mm diameter prototype eye 
plaques are shown in Figures 9 and 10. The main part of both prototypes is a quartz substrate in 
the shape of a spherical cap, with a layer of 124Xe ions implanted at the inner surface. For the first 
prototype, created in phase I of the project and shown in Figure 9, a 0.5 mm pure gold (Au 99.99) 
backing conforming to the spherical cap was attached to the rear side of the quartz substrate and 
both were encapsulated in a polymer enclosure prior to activation. The second prototype, shown 
in Figure 10, was created for phase II of the project. For the second prototype, the 0.3 mm thick 
quartz substrate with the layer of implanted 124Xe ions was encapsulated in a 0.125 mm thick 
enclosure of titanium prior to activation. 
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For the second prototype, the radius of curvature of the concave surface of the eye plaque attached 
to the sclera was 12.2 mm, similar to the 12.3 mm of the COMS plaques31.  
 
 
Figure 9. Cross section and bottom view (looking from the concave surface of the plaque) of the 
first prototype plaque. 
 
An exploded view of the quartz substrate and the parts of the titanium encapsulation of the 
 second prototype are shown in Figure 11. Pictures of the parts of the second prototype and the 
encapsulated eye plaque are shown in Figure 12. 
After activation, a 0.5 mm pure gold (Au 99.99) backing was attached to the plaque. The gold 
backing in the shape of a spherical cap was continued as a cylinder, called the “lip” in COMS 
0.5 mm
76°











plaques31, but has no attached suture lugs. The outer diameter of the lip was 18.5 mm and its height 
was 0.5 mm. The main role of the lip is to shield normal structures of the eye adjacent to the plaque 
as defined in the COMS protocol. 
  
Figure 10. Cross section and bottom view (looking from the concave surface of the plaque) of the 
second prototype plaque. 
The apparent activities of the first and second prototype eye plaques were estimated from exposure 




Figure 11. An exploded view of the second prototype plaque’s encapsulation without the gold 
backing. 
 
Figure 12. Second prototype quartz substrate before implantation (left) and after implantation with 








The collimator was fabricated from 0.13 mm thick pure gold (Au 99.99) in a form of a spherical 
cap and had a radius of curvature of 12.2 mm in order to conform to the concave surface of the 
eye plaque. The prototype collimator tested in this work is shown in Figure 13. 
 
Figure 13. Special collimator configuration. Collimator holes of 0.1 mm diameter are spaced 0.13 
mm apart in a hexagonal array. Dimensions in the drawing are in inches, since it was a production 
drawing. 
 
The tested collimator consisted of a 2.0 mm x 1.09 mm area around the central axis of the plaque 
which had 128 0.1 mm diameter holes separated by 0.13 mm in a hexagonal array. 
2.2 Solid Water “eye” phantom. 
Our first eye plaque dosimetry experiment consisted of measurements performed on CCX 36 106Ru 
eye plaque using both radiochromic film in a water-equivalent solid phantom and a small 
semiconductor diode in a water tank. 
The radiochromic film measurements were done using a NIST-manufactured set of phantoms 
made of WT1 (RMI 457 Solid Water™) water-equivalent plastic (we are indebted to Dr. C. Soares 
for making his phantom available to us). The phantom, shown in Figure 14 below, is the same 
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phantom used for radiochromic film 106Ru eye plaque dosimetry at NIST described by Soares et 
al73 and has been used by NIST to provide dosimetric calibration to BEBIG from 2002 until 2012. 
 
Figure 14. One set of the NIST Solid Water phantoms for 106Ru eye plaque dosimetry. 
 
The phantom consisted of nine sets consisting of an upper spherical section each having a radius 
of curvature of 12mm, corresponding to the inner radius of BEBIG’s eye plaques and matching 
bottom parts. Each pair (set) enabled placement of a film in a plane perpendicular to the central 
axis of the plaque at a specified distance from the plaque’s inner surface varying between 0.5 mm 
and 10.0 mm, sandwiching it between the upper and bottom parts. The upper and bottom part of 
each set together with the film formed a hemisphere of a radius of 12 mm. The eye plaque was 
placed on the top of the upper section, and the thickness of the upper section defined the distance 
of the top surface of the film from the eye plaque. The phantom enabled TLD measurements as 
well. Figure 14 shows a holder disk for round TLDs. 
Using the NIST phantom the author learned that radiochromic film in a Solid Water phantom is a 
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reproducible high resolution technique which has the potential of measuring accurate dose 
distributions needed for precise treatment planning and delivery. 
On the other hand, the NIST phantom had several limitations for the purpose of our work. Placing 
the eye plaque on top of the phantom in a reproducible way without moving the parts of the 
phantom and the film was a real challenge. Even with the help of a specially designed jig this task 
was very complicated. An additional limitation of this measurement setup was complete lack of 
co-registration between the film and the eye plaque. This caused difficulties in identification of the 
positions of detected non-uniformities, and was an obstacle for two-dimensional (other than the 
measurement plane) or three-dimensional reconstruction of dose distributions. Another problem 
of these phantoms was their limitation to dosimetry of 106Ru plaques. They could not be used for 
125I plaques because of their BEBIG tailored geometry, and because 125I measurements require a 
scatter phantom. While 106Ru eye plaques dosimetry was the original aim of this work, we 
considered from the early days working on dosimetric challenges of 125I eye plaques. Therefore a 
phantom was designed in this work and described in detail in the published article42 which is part 
of this dissertation. This phantom enables: 
• Performing measurements on eye plaques using 106Ru as well as 125I or any other 
radionuclide or combination of radionuclides. 
• Precise reproducible positioning of the eye plaques with respect to the films, which can be 
kept in place intact for the duration of measurements for as long as weeks. 
• Co-registration between the plaques and films which enables reconstruction of 2D dose 
distributions at selected planes or 3D dose distributions from a set of films irradiated at 




Figure 15 and Figure 16 below are pictures of the actual phantom and its parts assembled for 
measurements of CCX 55 eye plaque, as well as of an exposed MD55-2 radiochromic film. CCX 





Figure 15. Picture of the “eye” phantom assembled for a CCX 55 plaque measurement with a MD-





Figure 16. Parts of the “eye” phantom configured for a CCX plaque. 
 
Figures 17 and 18 below show an assembly drawing of the “eye” phantom with a 106Ru eye plaque 
and of the assembled “eye” phantom with a 106Ru eye plaque. Both were not included in the 
published article42 for brevity. In both figures all parts except for the eye plaque are made of Solid 
Water, different shades and colors are used in order to visualize the different parts. Obviously, the 
parts of the phantom which come in contact with the eye plaque have to be designed and 














There are a few important points which were not mentioned in the paper42, again for brevity. When 
the plaque is placed on top of the spherical part of the phantom, its lower border, for example the 
“lip” of a COMS plaque should not be in contact with the flat surface of the upper phantom insert 
which holds the spherical part, but should be above it, even by a small fraction of a mm, which 
can be inspected visually. Apparently the plaques have mechanical tolerances, and if the “lip” is a 
little longer this may create an air pocket between the inner concave surface of the plaque and the 
top of the spherical part of the phantom. In this case the dosimetric results will be wrong. This 
happened to us with a set of measurements of a 106Ru eye plaque. Some of the phantom parts had 
to be re-done and the measurements repeated. The other lesson was learned with larger plaques, 
like the 20 mm COMS plaque. Since we tried to perform measurements every mm starting with 
the inner concave surface of the plaque, there were a number of measurement planes inside the 
plaque. Creation of a single set of inserts enabling one to put films in, let’s say, four planes inside 
the plaque, even one film at a time, would create a very unstable construction. Therefore, the 
solution was to have a number of sets for the measurements inside the plaque, similar to the sets 
in the NIST phantom shown in Figure 14. For example, the 20 mm COMS plaque required four 
such sets. Obviously the eye plaque would still be held in place since its suture lugs would fit into 
the holes in the phantom. The small round films, which fit inside the plaque cannot be marked 
using a needle, like the larger films, which was very important for controlling the orientation of 
the films (to minimize polarization effects during film readout) and for co-registration of the films 
and the plaques. Therefore the reference orientation of these films was marked using a thin 
permanent marker prior to punching them from the page of film and then these films were 
positioned in the phantom making sure that the reference orientation matched the direction of the 
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large films; this direction serves as one of the coordinate axes in the scanning and analysis process 
(the Y axis). 
The phantom parts for measurements on the second prototype of the novel 125I eye plaque together 
with the second prototype are shown in Figure 19. 
The phantom drawings for dosimetry of 106Ru eye plaques are part of the published article42, while 
the drawings for the dosimetry of the 20 mm COMS plaque are shown in Figures 20 and 21 below. 
The phantom and its parts configured for the 20 mm COMS eye plaque measurements are shown 
in Figure 22, while the assembled phantom with the 20 mm COMS plaque and the phantom cover, 
which was created as an imprint of the backing of the eye plaque, conforming to it and holding the 
eye plaque in place, are shown in Figure 23. 
For 125I measurements the “eye” phantom has to be inserted into a scatter phantom which would 
model the irradiation conditions with a high degree of accuracy. Dosimetry of 106Ru does not 
require a scatter phantom due to the short range of the beta particles and relatively small photon 
component. As explained in the published article42 the latter statement was tested irradiating 106Ru 
eye plaque films with and without a scatter phantom; there was no measurable difference. On the 
other hand even for 106Ru measurements we placed the “eye” phantom with the eye plaque and 
film into a 50 mm diameter cylindrical hole at the center of a 30 cm x 30 cm x 3 cm Solid Water 
slab which was on top of a 30 cm x 30 cm x 5 cm Solid Water slab and covered by another 30 cm 
x 30 cm x 5 cm Solid Water slab in order to create full backscatter, and a stable measurement 
environment, so if the film was trying to curve, it would not be able to push the phantom open or 





Figure 19. Picture of the top view of the phantom body and its various inserts for measurements 
of the second prototype of the novel 125I eye plaque. The top view of the concave side of the second 
prototype eye plaque is at the bottom right. 
 
The measurements of the first prototype of the novel 125I eye plaque were done in a “head” 
phantom mimicking scatter conditions when irradiating a patient’s eye, i.e., having an eye-air 
interface similar to the “eye-head” phantom used by Chiu-Tsao et al56. The 3 cm thick Solid Water 
slab with the phantom and eye plaque was placed on top of a 0.5 cm thick 30 cm x 30 cm Solid 
Water slab held in the air by two Styrofoam blocks at its sides and covered by additional 15 cm 
thickness of 30 cm x 30 cm Solid Water slabs. This created scatter conditions similar to a realistic 
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scenario of eye plaque treatment, having scatter from the patient head and lack of scatter due to an 
eye-air interface. In this measurement setup the eye plaque was placed at the posterior aspect of 
the eye approximately 2.5 cm from the eye-air interface. 
Measurements of the second prototype of the novel 125I eye plaque were done in a full scatter 30cm 
x 30cm x 30 cm Solid Water cube created by placing the 3 cm thick slab with the phantom on top 
of 13.5 cm thickness of Solid Water slabs and covering it with 13.5 cm thickness of Solid Water 
slabs in order to compare the results with Monte Carlo simulations by Implant Sciences. 
The same full scatter phantom was used for dosimetric characterization of the 20 mm COMS eye 
plaque in order to test the BrachyDose Monte Carlo simulations by Thomson et al54 and Plaque 
Simulator calculations. Calibration of radiochromic film for 125I eye dosimetry using a calibrated 




Figure 20. Cross section of the Solid Water “eye” phantom shown with the 20 mm COMS eye 





Figure 21. Top view of an insert of the “eye” phantom with the 20 mm COMS eye plaque, inserted 
into the phantom, showing the key structures (Solid Water pins), and holes for marking the films 
(all dimensions in mm). The key structures are solid black for visibility. A – A marks the cross-




Figure 22. Solid Water “eye” phantom with its various inserts for measurements of the 20 mm 




Figure 23. Solid Water “eye” phantom with the fully loaded 20 mm COMS plaque assembled for 
measurement and the upper part of the phantom with the imprint of the plaque. 
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The Solid Water slabs used for building the phantom and subsequently all its parts, as well as the 
3 cm thick Solid Water slab with the cylindrical 50 mm hole were originally purchased as non-
certified Solid Water and their exact material composition was not known. In preparation for 
Monte Carlo simulations there was a need to know the material composition of the two slabs. The 
author asked the company Gammex (Middleton, WI, Sun Nuclear Corporation) for help. The 
company was able to locate the information by the serial numbers of the slabs, as presented in 
Table 2 below: 
 3.0 cm slab with 5.0 cm hole Phantom and its parts 
 Batch 992 (s/n 457 9992 4) Batch 11218 (s/n 457 11218 2) 
Hydrogen (H) 8.402 8.399 
Oxygen (O) 18.340 18.312 
Carbon (C) 68.970 69.017 
Nitrogen (N) 1.978 1.962 
Calcium (Ca) 2.31 2.31 
Chlorine (Cl) 0.0 ? 0.0 ? 
Density g/cm3 1.0412 1.0477 
 
Table 2. Elemental composition of the two Solid Water slabs used for creation of the “eye” 
phantom and measurement setup as percent by weight by element. The chlorine content was not 
reported, but since it is usually reported as only 0.1%, it was assumed to be 0.0%. 
 
The densities of the slabs in Table 2 were calculated by us shortly after their purchase weighing 
each slab using a precise Mettler (Mettler Toledo, Columbus, OH) scale, which we calibrated using 
standard weights and measuring its dimensions using Starrett rulers and calipers. 
A potential problem with the elemental composition of Solid Water is described in the published 
article42. There are two kinds of Solid Water, which differ in the calcium content, either 2.3% or 
1.7%, which results in substantial dosimetric differences when used for low photon energy 
dosimetry135. We were personally warned by Dr. Williamson, the Editor-in-Chief of Medical 
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Physics, that the company may report the wrong calcium content, which happened to him when 
conducting an experiment described by Patel et al138 and suggested that we should perform a 
chemical analysis of the phantom. Therefore a sample of the phantom was sent for chemical 
analysis to Analytical Answers, Inc. (Woburn, MA), the same laboratory used by Patel et al138. 
The result of gravimetric ashing and scanning electron microscopy/energy dispersive X-ray 
spectroscopy revealed calcium content of 2.32 ± 0.06% consistent with the manufacturer’s report. 
All our other Solid Water material was purchased as certified Solid Water with 2.3% calcium 
content as well. 
2.3 Radiochromic film. 
At the beginning of this work there were available two types of GAFCHROMIC film: HD-810 
and MD-55-2. The MD-55-2 type used for dosimetry of the CCX 36 eye plaque required a dose 
of about 30 Gy in order to achieve an optical density of about 0.5, which can be reasonably used 
for extraction of dosimetric data. A 30 Gy dose to the film required irradiation times between a 
day and a week, depending on the film distance from the plaque, for dosimetric characterization 
of a standard activity 106Ru eye plaque. The HD-810 film type was not considered for this project 
since it required a 100 Gy dose for the same optical density which would result in considerably 
longer irradiation times. Therefore MD-55-2 film was used for dosimetric characterization of the 
CCX 36, CCX 41 and CCX 55 106Ru eye plaques. The CCX 36 eye plaque was characterized using 
MD-55-2 Lot #37350. CCX 41 and CCX 55 eye plaques were characterized using MD-55-2 film 
Lot # I1215. 
Two new types of film were under development when this work started and were tested when they 
became available: HS and XR-T. The HS film was supposed to be somewhat more sensitive, but 
otherwise similar to MD-55-2 film. Upon testing of HS film Lot # 30263-1-C1, its sensitivity was 
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not found to be a significant improvement over the MD-55-2 Lot #I1215 already in use, as can be 
seen in Figure 24, since even the sensitivity of the film batches could be quite different and it 
seems that MD-55-2 Lot # I1215 was on the better sensitivity end. Therefore HS film was not used 
in this work. Figure 24 compares optical densities calculated from pixel values as OD = log (I/I0) 
of films irradiated on a 60Co machine in identical conditions scanned on an Argus II scanner with 
a red acetate filter120. 
 
Figure 24. Comparison of optical densities of experimental HS film Lot #30263-1-C1 and MD-
55-2 film Lot #I1215. 
 
The XR-T film was 12 times more sensitive than MD-55-2 for 125I energy photons100. The XR-T 
film had additional high Z components (Br, Cs), in order to increase its sensitivity to low energy 
photons, but made this film not tissue equivalent and similar to silver-halide radiographic film. 



















HS Film Lot # 30263-1-C1
HS Film Lot # 30263-1-C1 Fitted
MD-55-2 Film Lot # I1215
MD-55-2 Film Lot # I1215 Fitted
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plaque, producing excellent results. The first development of our novel calibration technique for 
low energy photons described in the film calibration section was done with this film.  
While the general construction, elemental composition and other features of the XR-T film were 
described by Soares et al113, the particular lot used in this work had a 27 µm thick active layer with 
the following elemental composition (percentage by mass): H-6.9, C-46.6, N-8.6, O-14.8, Br-8.7, 
Cs-14.4, resulting in an effective Z = 26.6, as compared to effective Z = 6.27 for the standard 
GAFCHROMIC emulsion113. 
Since the old GAFCHROMIC emulsion films were inherently non-uniform, the technique of 
creating more uniform sub-film lots discussed in section 1.4 of the Introduction was applied for 
dosimetric measurements of CCX 41, and CCX 55 eye plaques using MD-55-2 film and of the 
first prototype of the novel 125I eye plaque using XR-T film, as well as for testing of the HS film. 
The new EBT2 and EBT3 films are much more uniform than older film types and have the blue 
dye component, which enables doing multi-channel dosimetry118, which was tested in this work. 
Dosimetric measurements of only one eye plaque, CCX 219, were done using EBT3 film and we 
did not see any difference in applying single-channel dosimetry vs. multi-channel dosimetry, but 
this definitely matters in measurements using large radiation fields and films, like IMRT QA118. 
Starting with EBT1 film, we randomized the eye plaques’ films and calibration films vs. their 
original position on the film sheet in order to avoid non-uniform coating trends. 
The new EBT film Lot #34141 2x2IL was immediately used for dosimetry of 106Ru eye plaques 
CCX 104, CIA 156, and CCA 892.  
EBT film Lot #34351-05 was used for dosimetry of the second prototype of the novel 125I eye 
plaque. The EBT emulsion’s sensitivity is similar to the sensitivity of the XR-T film, but without 
adding high Z components, thus maintaining near tissue equivalency113. The EBT emulsion films 
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are designed to be much more uniform than the former GAFCHROMIC emulsion films, which 
was verified by our own measurements and published by others139. Therefore no special selection 
of parts of the film sheets was implemented when cutting films for measurements as was done for 
pre-EBT films. 
The cross section of the composition of the new EBT film is shown in Figure 25 below, as well as 




Figure 25. Cross section of GAFCHROMIC EBT film. 
 
Since the film’s sensitivity goal was 200 cGy (a typical patient dose in radiation therapy) in order 
to make it usable for IMRT QA, the film had to be a double emulsion film, having two active 
layers protected by clear polyester on both sides. The total thickness of the film was 0.20 - 0.25 
mm as measured for different production batches using a micrometer vs. expected nominal 0.234 
mm. The thickness variation between different production batches points toward sensitivity 
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variation of different production batches as was the case of pre-EBT films. The thickness of EBT 
film is similar to the thickness of the MD-55-2 film used by the author previously. Therefore, while 
the new film became of significant value for this work, the thickness continued to be a limiting 
factor of this film from becoming an “ideal” dosimeter for eye plaque dosimetry. The thickness 
limitation is very important for beta dosimetry with dose gradients of ~30%/mm, in the proximity 
of the concave surface of the plaque, where the dose gradient is highest. This thickness and design 
make the EBT film very rigid. It was impossible to bend it to a small radius of curvature in order 
to measure the dose close to the surface of an eye plaque. Therefore, the surface dose, which is the 
dose to the outer sclera, could not be reliably measured, which is important when there is a 
limitation on the maximum scleral dose which can be delivered or a requirement to deliver a 
minimal scleral dose as prescription dose. No other dosimeter can measure the dose rate closer 
than about 0.5 - 1.0 mm from the surface of the plaque due to geometrical and mechanical 
limitations of the smallest detectors (TLD’s, plastic scintillators, semiconductor diodes)41. For 
106Ru eye plaques the surface dose reported by the manufacturer is extrapolated from plastic 
scintillator measurements the closest of which was about 0.6 mm from the surface (this was later 
improved to 0.48 mm). In the Introduction it was noted that 106Ru eye plaques can have substantial 
dose non-uniformities which result from non-uniform distribution of radioactive material in the 
active layer. These non-uniformities cause dosimetrically hot or cold spots on the sclera. This is 
another reason to measure accurately the surface dose. Surface dose measurements would also 
provide precise information about the dose fall-off at the edge of the plaques enabling selection of 
appropriate plaque sizes for tumor coverage. Similar considerations apply to the novel 125I eye 
plaques of designs similar to 106Ru plaques studied in this work. Even COMS plaques which are 
based on TG-4353 dosimetry have large dosimetric uncertainties, since TG-43 parameters are not 
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well defined in the near field and the near field effects of the Silastic insert and gold alloy backing 
are not well established, as already discussed. Therefore, International Specialty Products created 
per our request a special thin GAFCHROMIC film, named EBT1, which consists of a single layer 
of the film shown in Figure 25 (shown in Figure 4b of the published article42) and shown in Figure 
26 below. In this film the active layer is covered just by 3 microns of protective coating on one 
side. This film permits nearly direct contact of the film with the eye plaque surface for surface 
dose measurements and is sufficiently flexible for this purpose. The sensitivity of the film is half 
of the double emulsion film, but still satisfactory for eye plaque dosimetry (~400 cGy for optical 
density of 0.5). 
 
 
Figure 26. Cross section of special thin GAFCHROMIC EBT1 film. 
 
EBT1 film Lot #35314-4H was used in this work for dosimetric characterization of CCX 129 106Ru 
eye plaque, and of the 20 mm fully loaded COMS plaque. 
Following the development of special thin EBT1 film, ISP developed for this work special thin 
EBT2 film, Lot #040309-1B, which was used for 125I film calibration experiments. Its active layer 
is covered only by a 4 micron surface layer and its structure is shown schematically in Figure 27. 
surface layer - 3 microns
active layer - 17 microns
clear polyester - 97 microns
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The shift from EBT film to EBT2 and then EBT3 film happened when ISP changed the film 
technology from EBT film to the next generations. The author of this thesis was testing the newest 
types of film and received special batches of thin films manufactured specifically for this thesis. 
The newest film, EBT3, is shown schematically in Figure 28. It uses an improved coating 
technique resulting in more uniform film than EBT2. EBT3 film was used for Monte Carlo 
comparison with EBT film when studying the dose differences in Solid Water with different 
calcium content. EBT3 film was used for the Monte Carlo comparison, since its structure with 
clear polyester layers on both sides of the film was similar to the structure of EBT film used for 
the novel 125I eye plaque project for which Monte Carlo simulations were done. Regular EBT3 
film was not used for actual measurements in this work, since at this point we used only special 




Figure 27. Structure of special thin GAFCHROMIC EBT2 film. 
surface layer - 4 microns
active layer - 35 microns





Figure 28. Structure of GAFCHROMIC EBT3 film. 
 
 
Based on our recommendations and results, Ashland currently delivers commercially unlaminated 
EBT3 film, which consists of a 125 µm thick clear polyester substrate and a 14 µm thick active 
layer without any protective coating as shown in Figure 29 and Figure 4c of the published article42. 




Figure 29. Structure of unlaminated GAFCHROMIC EBT3 film. 
 
clear polyester - 125 microns
active layer - 28 microns
clear polyester - 125 microns
    active layer - 14 microns
  clear polyester - 125 microns
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2.4 Preparation of films in the appropriate sizes and shapes and some film handling aspects. 
The eye plaque dosimetry technique presented in this work requires precise cutting of round films 
with diameters as small as 8.5 mm and thin 3 mm wide strips, which could be placed on the concave 
surface of the eye plaques. The cutting had to be done without creating rough damaged edges 
resulting in air gaps between the films and parts of the phantom and without separation of layers 
of the films, which would make all or large part of the film unusable. Radiochromic films have 
between two and seven layers, which can easily separate during cutting113. MD-55-2 film is a 
double active layer film, consisting of a total of 7 layers; XR-T film is a single active layer film, 
consisting of a total of three layers; EBT film, as shown in Figure 25 has two active layers for a 
total of five layers, and EBT3 film has again a single active layer for a total of three layers, as 
shown in Figure 28. Even the thin unlaminated films have at least two layers. Since the films are 
sensitive to scanner light polarization, the direction of cutting and subsequent scanning has to be 
strictly observed. First, the sheets of films are cut into strips, preserving and marking the proper 
directionality, using an office paper cutter, which damages approximately 5 mm of film from the 
cutting edge. Therefore the strips are cut accordingly wider to enable creation of round films with 
appropriate diameters. Initially round films were punched from these strips using a set of round 
punches created especially for this purpose by MSKCC’s Instrument Shop using a press or just a 
hammer for the smallest punches. Since these punches still left rough edges and caused separation 
of layers, they created a set of special punches using precise instrument cutting dies custom made 
by Dayton Lamina Corporation (Dayton, OH). A picture of the set of punches is shown in Figure 
5 of the published article42. The set includes seven round cutting dies enabling punching round 
films with diameters of 0.335” (~8.5 mm), 0.413” (~10.5 mm), 0.492” (12.5 mm), 0.551” (~14.0 
mm), 0.590” (~15.0 mm), 0.630” (~16.0 mm), and 0.689” (~17.5 mm). In addition the set includes 
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a 30 mm diameter cutting die with two semi-circle cutouts as shown in the drawing in Figure 30, 
which is the main film size of the “eye” phantom. The cutouts are needed to accommodate the key 
structures of the phantom. Later a cutting die for punching 3 mm wide 30 mm long film strips 
which could be attached to the concave inner surface of the plaques was added to the set and is 
shown in Figure 31. 
 
 
Figure 30. Cutting die and matrix for 30 mm diameter films. All dimensions in inches. 
 
In order to use these cutting dies, a special punching device is shown in Figure 5 of the published 
article42 and assembled in Figure 32. Its cross section showing the design details is shown in Figure 
33. The cutting dies resulting from this custom fabrication cut films without any damage, leaving 





Figure 31. Cutting die and matrix for 3 mm wide 30 mm long film strips. All dimensions in inches. 
 
Starting with EBT film, the sheet of film, usually 8” x 10”, is cut into sufficiently wide strips in 
the standard direction decided in our protocol, which is the portrait orientation, using a high quality 
office cutter with a roller knife. In order to observe this direction and control the strips position on 
the sheet, the film sheet is attached to a piece of graph paper, cut along the lines of the graph paper 
in the portrait orientation and the number of the strip is written with a marker pen at the upper left 
corner (our convention). Then the strips are either cut by the same paper cutter into rectangular 
films (usually 2.0 cm x 2.0 cm) for calibration purposes or used for punching round or other shaped 
films, marking at the upper left corner of each rectangular piece the coordinate of the piece on the 
sheet in the form of the row#-column#. Then each calibration or punched film is kept in a separate 
light-tight envelope which has the two-digit number of the film. Starting with EBT films, the film 
uniformity was greatly improved and there was no need to create sub-batches along the direction 
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of coating, as the author did for MD-55-2 films. Some degree of non-uniformity, however, 
remained. Therefore, whether the films are used for calibration or eye plaque dosimetry purposes, 
starting with EBT1 film, the films were randomized with the respect to their position on the film 
page using the random number generator function of Microsoft Excel, eliminating the possibility 




Figure 32. Assembled film cutting die punching device. 
 
When punching the 30 mm diameter films with cutouts the strip has to be properly held in the 
punching device. The cutouts sufficiently define the direction in the phantom, which is then 
marked by needle marks, as described in the description of the phantom design42. The 3 mm wide 
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strips are always punched in the long direction of the strip using the attached graph paper. When 
it comes to punching the smaller round films without cutouts, the proper direction is marked on 
the film piece to be punched in two locations along the diameter coinciding with the portrait 
orientation of the page, prior to punching. In addition these marks are used for matching the film 
position and orientation with the eye plaque during the measurement process. 
Handling tips for radiochromic film have been described in detail113. The issue of moisture content 
and equilibration with the environment was discussed in the Introduction. Thus, films used for 
calibration and eye plaque measurements were pre-cut usually several days prior to irradiation, at 








2.5 Film scanning. 
All films used in this work were read-out using one of three CCD scanners. All scanning was 
done in transmission mode of the scanners. Initially, an AGFA ARCUS II flatbed scanner 
(Agfa-Gevaert N. V., Mortsel, Belgium) was used. The scanning was done at 85 micron 
resolution with a red acetate filter120 and RIT113 Film Dosimetry software (Radiological 
Imaging Technology, Inc., Colorado Springs, CO). When this scanner became unavailable, a 
Vidar VXR 16 Dosimetry Pro 16 bit film scanner (Vidar Systems Corporation, Herndon, VA) 
was used. The scanning was done at 89 micron resolution with films placed into clear plastic 
sheet protectors together with a red acetate filter for XR-T film and with a yellow acetate filter 
(as recommended by the manufacturer of the film) for EBT film. The same RIT software was 
used for scanning. The third reader, with which most of the work was done was an Epson 
Expression 1680 flatbed scanner (Seiko Epson Corporation, Nagano, Japan) using EPSON 
Scan software in 48 bit RGB mode with all filters and image enhancements de-activated, 
followed by extraction of the red channel. The films were mostly scanned at resolutions of 254 
dpi (100 microns pixel size) or 512 dpi (50 microns pixel size). The red channel provides 
optimal response for GAFCHROMIC film113, but since the RIT software was limited to 
monochrome (16 bit) scanning, we had to use the red acetate filter for MD-55-2 film120. The 
yellow acetate filter was utilized for EBT film in order to maximize film response with the 
Vidar scanner. The calibration curves of MD-55-2 film Lot #I1215 scanned using the ARCUS 
II scanner with and without the red acetate filter are shown in Figure 34. 
 Scanned images were saved as TIFF files for further processing. Our standard scanning 
protocol, which was started using the Epson 1680 scanner, always included a preview scan in 
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order to equilibrate the film temperature with the scanner temperature followed by the 




Figure 34. MD-55-2 film Lot# I1215 calibration curve scanned with and without the red acetate 
filter. 
 
Since there were discussions in the literature (for example Lynch et al115) about the effect of 
scanner temperature and scanner stability on the dosimetry results, we tested possible effects on 
our scanning protocol for a period of time, scanning standard optical density tablets provided by 




















fitted with red filter
w/o red filter
fitted w/o red filter
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2.6 Calibration of film for absolute dosimetry. 
2.6.1 Calibration of radiochromic film for absolute 106Ru dosimetry. 
The published article includes a description of film calibration for 106Ru eye plaque dosimetry less 
charts of the calibration curves and their fitting with analytical functions, which were not shown 
for brevity. The calibration curve of MD-55-2 Lot #I1215 is shown in Figure 24. For dosimetry 
use it was fitted with an analytical function. Calibration curves of thin EBT1 film Lot#35314-4H 
and unlaminated EBT3 film Lot #02171601 are shown in Figure 35. Both calibration curves in the 
form of pixel values vs. dose were fitted with analytical functions suggested by the curve fitting 
program CurveExpert Professional software by Daniel G. Hyams, Madison, AL. The EBT1 curve 
was fitted with a function: 
 	 =
 ∗  +  ∗ 
 + 
 
The unlaminated EBT3 curve was fitted with a function: 
 	 =
 +  ∗ 
1 +  ∗  +  ∗ 
 
where a, b, c and d are fit parameters, which use the same letters, but have different values and 





Figure 35. Calibration curves of EBT1 film Lot #35314-4H used for dosimetry of CCX 129 plaque 
and unlaminated EBT3 film Lot # 02171601used for dosimetry of CCX 219 plaque. 
 
2.6.2 Calibration of radiochromic film for absolute 125I eye plaque dosimetry. 
Generally, old GAFCHROMIC films under-responded at low photon energies, which include 
those of the 125I source studied in this work. The exception is XR-T film, which over-responded at 
these energies, similar to silver halide radiographic film100, 113. EBT film was found to have 
minimal energy dependence101, 113 at 125I energies, but this could still depend on the particular lot 
used. Of some concern is that earlier reports noted possible dose rate dependence of 
GAFCHROMIC films119 or “temporal history mismatch”, when used for low dose-rate 
brachytherapy dosimetry140. Therefore both, XR-T Lot #K02b28XRT and EBT Lot #34351-05 






















model 3500 brachytherapy seeds (Implant Sciences Corporation). Special thin EBT1 Lot #35314-
4H and special thin unlaminated EBT2 Lot #040309-1B films were calibrated using a calibrated 
Model 6711 125I seed (Oncura, Inc., Arlington Heights, IL), thus eliminating both the energy and 
dose rate dependence of the response, but still potentially vulnerable to possible “temporal history 
mismatch”. 
This work developed a novel calibration technique for absolute 125I dosimetry, which creates a 
calibration curve from a single irradiated film, rather than the usual irradiation of a large number 
of films to single doses141. This approach improved the uncertainty of reading the optical density 
pertaining to a single dose on a film irradiated by a seed. Unlike using large uniform fields for film 
calibration on a linac, in the case of calibration using a brachytherapy seed, the single dose is 
understood as the point dose on the film at the shortest distance from the seed center, usually at 
the center of the film. Technically, this should be a single pixel, but the optical density of a single 
pixel is affected by image noise and film non-uniformity and, considering mechanical 
uncertainties, it is even hard to decide which single pixel to use, as can be seen from a profile of 
pixel values through the center of a film (Figure 38). The calibration seed is placed into an opening 
at the center of the top surface of a specially designed phantom insert (Figure 36). The insert with 
the seed is placed as the top insert of the cylindrical body of the “eye” phantom filled with Solid 
Water inserts and a film is placed between the inserts under the seed at a specified distance from 
the seed center. The distance of the film from the seed should be more than 5 mm, since closer 
than 5 mm the TG-4353 dose is not well defined. The phantom with the seed and film is covered 
with a special flat top cover (without an impression for an eye plaque) and placed in the middle of 
a full scatter 30 cm x 30 cm x 30 cm Solid Water phantom for the required irradiation time. The 
latter is estimated using the TG-43 formalism53 in order to deliver a sufficiently high dose to the 
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center of the film, which would cover the dose range expected in the eye plaque measurements. A 
single film is irradiated under the described conditions. The irradiated film and an unexposed film 
are scanned according to the data analysis protocol of the particular experiment, including scanner 
model (calibration films and eye plaque films have to be scanned on the same scanner), scanning 
time delay after end of exposure, and orientation on the scanner. The unexposed film is needed in 
order to provide the “0” dose background of the film. 
 
Figure 36. Seed calibration insert of the Solid Water “eye” phantom. 
 
The seed axis and a perpendicular axis passing through the center of the seed are marked on the 
film prior to irradiation using a thin needle through the holes in the insert. A typical irradiated film 
and an unexposed film are shown in Figure 37. Since the special thin EBT1 films tend to curl on 
the scanner, they were lightly taped in order to ensure good contact and avoid Newton’s rings. 
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The next step was to extract from the film data a profile of pixel values vs. coordinate on the film 
centered exactly under the center of the seed in the direction perpendicular to the seed axis. This 









Figure 37.  On the left special thin EBT1 Lot #35314-4H film 6-1 irradiated by a calibrated 125I 
seed, on the right unexposed film 4-1 from the same Lot. 
 
Films were scanned at resolutions of 89 – 100 µm, resulting in profiles consisting of many data 
points. These profiles were slightly shifted, usually about one pixel, in order to make them 
symmetrical vs. the seed center, similar to what is done with water tank profiles of a linear 
accelerator, in order to exclude possible mechanical setup uncertainties. The profiles were than 
mirrored and averaged in order to improve noisy data and exclude possible film non-uniformity. 
A typical raw profile, consisting of 200 points extracted from film data prior to centering and 
symmetrization is shown in Figure 38.  
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The expected dose on the film at each point of the profile is calculated using the line approximation 
of the TG-43 formalism53, while the distance of the points of the profile on the film from the seed 
center is derived using a simple geometrical calculation. Use of a central profile perpendicular to 
the seed axis eliminated the need to account for the 2D anisotropy function F(r, θ). Substituting 
the distance from the film center with dose gives a curve providing the dependence of pixel values 
on the film on dose, which is the calibration curve of the film at the given irradiation and scanning 
conditions.  
 
Figure 38. Raw pixel value profile vs. distance from film center along a line perpendicular to the 
direction of the calibration seed axis at the seed center for film 6-1 of EBT1 Lot #35314-4H shown 
in Figure 37. 
The resultant calibration curves were further fitted with analytical functions for use in the film 
dosimetry process. A set of Microsoft Excel spreadsheets keeping all the data and performing the 
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The film calibration process described above produces a very fine-resolution calibration curve 
which would be equivalent to irradiation of a very large number of films to single doses, for 
example at least 100 for the case shown in Figure 38.  
We then compared the calibration technique described here to a calibration curve derived from 
irradiating many films and using the center dose point only, and found them equivalent, except 
that this technique is more efficient and provides a much higher resolution. In some cases, one film 
does not cover the full dose range needed for the experiment, due to geometrical limitations of the 
“eye” phantom. In such cases, it is possible to irradiate a second film to a different dose such that 
both films cover the expected dose range and then combine the two calibration curves into one, a 
technique originally developed by Soares and McLaughlin142. Calibration curves for special thin 
EBT1 Lot #35314-4H and special thin unlaminated EBT2 Lot #040309-1B films created using the 
described technique are shown in Figure 39. Both curves were fitted with 5th order polynomials. 
The EBT1 calibration curve was created and used for dosimetry of fully loaded 20 mm COMS 
plaque, while the unlaminated EBT2 curve was created for testing purposes of the EBT2 film and 
of the calibration method. The surprising finding was that unexpectedly the shape of the curves is 
virtually identical, despite the fact that EBT2 film belongs to a chemically and technologically 
different generation of films. The average point by point ratio of the EBT1 fitted curve to the EBT2 
fitted curve is 1.14 with a standard deviation of 0.01. The particular EBT2 Lot is just more sensitive 
than the particular EBT1 Lot. Another surprise finding was observed when we compared the 
calibration curves of the EBT1 Lot #35314-4H calibrated using the calibrated 125I seed as shown 
in Figure 39 with the calibration curve of the same film Lot calibrated using 6 MeV linear 
accelerator electrons for 106Ru dosimetry of the CCX 129 eye plaque shown in Figure 35. The 
comparison is shown in Figure 40. Instead of the expected near energy independence of the EBT 
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family101, 113, we found that this EBT1 Lot has strong energy dependence at least at low photon 




Figure 39. Calibration curves of special thin EBT1 film Lot #35314-4H and special thin 
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Figure 40. Calibration curves of special thin EBT1 film Lot #35314-4H using a calibrated 125I 
seed and 6 MeV electrons. 
 
The calibration of the XR-T film Lot #K02b28XRT used for the film dosimetry of the first 
prototype eye plaque was done using a calibrated 125I I-Plant model 3500 brachytherapy seed. The 
film was placed at a depth of 5.73 mm under the seed (distance between the center of the seed’s 
long axis and the center of the film’s active layer) in the geometry described above in a full scatter 
30 cm x 30 cm x 30 cm Solid Water phantom. The film was irradiated for almost 20 days (475 
hours 21 minutes) in order to achieve a sufficient dose, since the calibrated seed had air kerma 























the film was scanned 7 days after the end of the irradiation in order to be at a stable post-exposure 
optical density, minimizing or avoiding possible “temporal history mismatch”140. The film was 
scanned using the Vidar VXR 16 Dosimetry Pro 16 bit film scanner at 89 µm resolution. The 
scanning was done using RIT film dosimetry software. Since the Vidar scanner moves the film 
through a fluorescent light source/CCD combination, the small film was placed into a clear sheet 
protector prior to scanning together with a red acetate filter. The film was scanned at the center of 
the scanner in order to minimize potential film-scanner positional effects. In addition, the marked 
axis of the film was made to coincide with the direction of scanning in order to preserve the film 
orientation for consistent film directionality. The scanned film data were analyzed using MSKCC’s 
film dosimetry Contour program. The expected dose at the depth of the center of the active layer 
of the film was calculated using the line source approximation of the TG-43 formalism53. The seed 
data set was taken from Duggan and Johnson143, since our measurements of the first prototype eye 
plaque predated the publication of the consensus data set for the 125I I-Plant model 3500 
brachytherapy seed.  
The calibration of the EBT film used for the film dosimetry of the second prototype eye plaque 
was again done using a calibrated 125I I-Plant model 3500 brachytherapy seed. The film was placed 
at a depth of 6.71 mm under the seed, in the geometry described above in a full scatter 30 cm x 30 
cm x 30 cm Solid Water phantom. 6.71 mm is the distance between the center of the seed’s long 
axis and the center of the film, which in this case does not coincide with a center of an active layer, 
since EBT film has two active layers, as shown in Figure 25. The calibrated seed had an air kerma 
strength of 5.604 U at the beginning of the irradiation. The film was irradiated for 24.175 hours so 
that the TG-4353 calculated dose expected at the film center was 313.9 cGy, this time using the 
published consensus data set137. The irradiated film and an unexposed film were scanned 24 hours 
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after exposure using the Epson Expression 1680 flatbed scanner in 48 bit color followed by the 
extraction of the red channel instead of using a red filter, since the scan was done in a color mode. 
The analysis of the films was done using MSKCC’s film dosimetry Contour program. For scanning 
on the Epson scanner the films were placed at the center of the scanner bed, in order to avoid 
scanner induced light scatter non-uniformity, with the film axis oriented in the portrait direction 
of the scanner in order to preserve the film orientation. 
As mentioned above, calibration of films for the fully loaded 20 mm COMS plaque experiment 
was done using our novel technique, but still irradiating many films in order to better study 
different aspects of the approach. This was possible since we received a very strong seed, with 
27.45 U air kerma strength, which kept irradiation times reasonably short. For calibration of EBT1 
film Lot #35314-4H, the films were placed 5.6315 mm under the seed (5.62 mm phantom thickness 
+ 0.0115 mm film thickness to the middle of the active layer). Eleven films were irradiated to 
doses 50.75 cGy – 1,430.96 cGy at the film center. Irradiation times varied from ~41 minutes to 
almost 18 hours. For calibration of EBT2 film Lot #040309-1B, the films were placed 5.6415 mm 
under the seed (5.62 mm phantom thickness + 0.0215 mm film thickness to the middle of the active 
layer). Eight films were irradiated to doses 71.51 cGy – 1,112.71 cGy at the film center and 
irradiation times varied between ~2 and ~25 hours. As above, all irradiations were done in a full 
scatter 30 cm x 30 cm x 30 cm Solid Water phantom. Prior to irradiations all films were 
randomized as to their positions on the respective film sheets using MS Excel’s random number 
generator. All films, including unexposed films, were scanned 24 hours after the end of the 
irradiation using the Epson 1680 Expression scanner in 48 bit color followed by the extraction of 
the red channel. The films were placed at the center of the scanner bed orienting the original 
portrait orientation of the film page in the long direction of scanning (portrait orientation of the 
 71 
 
scanner) as per our usual scanning protocol. The scanned data were analyzed using MSKCC’s 
Contour film dosimetry program. 
2.7 Eye plaque dosimetry and data analysis. 
Details of this subject are fully described in the published article42, which is attached to the end of 
this thesis as Appendix 1.  Films were irradiated one at a time, in order to deliver approximately 
the same dose to each film, which would produce the desirable optical density of about 0.5 in the 
high dose area of the film. For MD-55-2, this dose was about 30 Gy, for XR-T film it was about 5 
Gy, for EBT film, about 200 cGy, and for thin special EBT1 film and unlaminated EBT2 film it 
was about 400 cGy. 
The MD-55-2 films were scanned 48 hours after irradiation, while the XR-T films were scanned 
7 days after irradiation, due to extremely long irradiation of the calibration film as a very weak 
calibration seed was utilized. All other films were scanned 24 hours after the end of irradiation in 
order to let the polymerization process stabilize and have all films scanned at the same level of 
post-exposure growth98. If the calibration films were scanned 24 hours after irradiation, then the 
eye plaque films were scanned after 24 hours as well. Both calibration and eye plaque films were 
always placed at the center of the scanner bed lightly attached to it using adhesive tape at the edges 
of the film in order to avoid Newton’s ring artifacts. Films were scanned in the same orientation, 
usually portrait with respect to the original sheet of film. In general, CCD scanners suffer from a 
lateral response artifact123, 124 resulting in decreased pixel values (increased measured optical 
density) toward the lateral edges of the scanner bed. However, since the films used in this work 
were small and always positioned at the same location at the center of the scanner, reader bed 
positioning corrections were not required113. Special attention was given to the temporal stability 
of the scanners, monitored by periodic scanning of reference optical density tablets.  
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Film scanning produces a point-by-point, high resolution 2D optical density map of the irradiated 
film. Applying the calibration curve to each pixel of the optical density map converts the latter into 
a 2D dose distribution. Since each film was exposed at different dates and times, the 2D dose 
distributions were converted to dose rate distributions at a certain reference date and time, using 
the exposure dates and times, and decay constants of the radionuclide in question. The film analysis 
was always done using MSKCC’s Contour software package, which was customized in order to 
accommodate the requirements of this work. The ability to use scanned films in the form of TIFF 
files and circular regions of interest were added to the software. 
2.8 Silicon diode dosimetry of the novel 125I eye plaque. 
The use of the silicon diode as a secondary dosimeter for 106Ru eye plaques was described in detail 
in the published article42. The same p-type silicon diode, the Scanditronix Stereotactic Field 
Detector (SFD) model DEB050 (Scanditronix Medical AB, Uppsala, Sweden, currently IBA 
Dosimetry GmbH, Schwarzenbruck, Germany) in a Scanditronix RFA200 water tank was used for 
dosimetry of the first prototype novel 125I eye plaque. Unfortunately, after just two films and diode 
measurements, this plaque developed a radioactive leak and the experiments were discontinued. 
This diode detector has a 60 µm typical effective thickness of the measurement volume with a 0.6 
mm ± 0.1 mm detector diameter, and a distance of 0.61 mm ± 0.15 mm displacement of the 
effective measurement point from the front surface of the detector. Externally, the detector is a 4.0 
mm diameter cylinder which was oriented along the central axis of the eye plaque. The closest 
measurement point of the diode was 0.87 mm from the inner surface of the plaques due to the 
concave shape of the plaques and the 4.0 mm diameter of the diode both of which limited how 
close the diode can come to the surface of the plaque. The eye plaque was attached using Dow 
Corning High Vacuum grease (Dow Corning Corporation, Midland, MI) to the cap of the Solid 
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Water “eye” phantom placed upside down, and the cap was attached using the same grease to a 
Lucite base positioned at the bottom of the water tank. The cap was used for this purpose since it 
had a customized imprint of the particular eye plaque. A special Lucite centering jig was created 
to assure that the diode was precisely centered on the central axis of the eye plaque and was not 
displaced laterally from the axis. The arrangement is shown in Figure 6 of the published article42. 
After setup, the Lucite jig was removed for measurements. The water tank’s mechanism and 
software were used to position and drive the diode detector. For eye plaque measurements, the 
center of the plaque’s inner concave surface was covered by only 35 mm of water in order to create 
a water/air interface similar to the Solid Water/air interface created when the “eye” phantom was 
inserted into the “head” phantom for film measurements.  For the first prototype of the novel 125I 
eye plaque, depth dose measurements were performed every 0.5 mm from 0.87 to 26.87 mm from 
the inner surface of the plaque. For absolute depth dose measurements, the detector was connected 
to a Memorial Sloan-Kettering Cancer Center ADCL calibrated in-house built electrometer model 
821 and two readings were taken at each point: each integrated for 60 seconds.  Then the results 
of both measurements were averaged. 
For 125I novel eye plaque measurements the diode was calibrated for absolute dosimetry in the 
same Scanditronix RFA200 water tank with the same MSKCC’s in-house built electrometer model 
821 using the same calibrated 125I I-Plant model 3500 brachytherapy seed, which was used later 
for XR-T Lot # K02b28XRT film calibration, in a setup similar to the eye plaque setup. At the 
time of the calibration the air kerma strength of the seed was 1.6229 U. The seed was attached to 
a Solid Water disk using Dow Corning High Vacuum grease, and the latter was attached using the 
same grease to the Lucite base positioned at the bottom of the water tank. The seed was located at 
an approximately 13 cm depth of water at 22°C during measurements, the same temperature as 
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during eye plaque measurements. The diode was first brought in contact with the seed and then 
retracted to a distance of 5.01 mm between the seed long axis and the effective measurement point 
of the diode using the mechanism of the RFA200 water tank, where a set of four readings was 
recorded for 1, 2, 3, and 4 min. Then the diode was retracted to two more distances from the seed, 
5.51 mm and 6.01 mm, and the measurements were repeated. The expected dose at the diode was 
calculated using the line source approximation of the TG-43 formalism53, while the seed data set 
was taken from Duggan and Johnson143 as described for the XR-T film calibration. The diode 
calibration taken as the average dose rate per reading at the three distances was 1270.57 cGy/hour-
reading with a standard deviation of 34.70 cGy/hour-reading at the appropriate reference date. The 
diode results were in good agreement with film dosimetry results, even though per the 
manufacturer’s specifications the diode was rated for energies above 1 MeV, and silicon 
semiconductor diodes have been used in the past only for relative dosimetry of 125I seeds107-109 and 
for relative dosimetry of 125I eye plaques110. The mean spectral energy of 125I is virtually unchanged 
with distance from the source in water106, 144 and the relative absorbed-dose energy response 
correction for 125I sources measured with a silicon detector is constant with the distance from the 
source144, which qualifies the silicon diode for relative dose measurements along the central axis 
of the eye plaques, and, if properly calibrated, for absolute dose measurements as used in this work. 
Measurements off the central axis would require testing the diode’s angular response at these 
energies, which was not done, but still profiles across the plaque in three planes perpendicular to 
the central axis of the plaque at distances 6.2 mm, 7.9 mm, and 15.6 mm from the center of the 
inner surface were obtained by scanning in the same water tank setup. For the scans the diode 
detector was connected to the water tank electrometer which was not calibrated for absolute 
dosimetry, therefore the scanning results are considered relative. 
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2.9 Monte Carlo simulations of the novel 125I eye plaque dosimetry. 
Implant Sciences Corporation performed numerous Monte Carlo simulations of the concept for 
the novel eye plaque; we compared in this work the expected dosimetry of the second prototype 
eye plaque calculated by Monte Carlo with the results of our absolute film dosimetry. Moreover, 
it should be noted that all our film calibrations, whether for 106Ru eye plaques, using 60Co machines 
or linear accelerators, or for 125I eye plaques, using calibrated 125I seeds, are done in Solid Water 
phantoms. The doses ascribed to pixel values of the calibration films are known in terms of dose 
to liquid water, since the 60Co machines, linear accelerators and 125I seeds are calibrated in terms 
of dose to liquid water using either TG-51145 (TG-21146 before that) or TG-4353. The eye plaque 
film dosimetry is done in Solid Water, even though the dose of interest in radiation therapy is dose 
to liquid water. Conversion of the absorbed dose measured in Solid Water to absorbed dose in 
liquid water may require additional corrections usually done by Monte Carlo132-135. Of special 
interest is the work by Meigooni et al135 which found that certain batches of Solid Water may have 
1.7% calcium content, while other batches may have 2.3% calcium content, and depending on the 
calcium content of the Solid Water, the Monte Carlo calculated dose conversion factors from Solid 
Water to liquid water may vary by as much as 5% for 125I. We performed analysis of our Solid 
Water and found that all our Solid Water has 2.3% calcium content as discussed in our published 
article42. Unfortunately, published works132-135 deal only with differences between absorbed dose 
in solid water equivalent materials and liquid water, but do not analyze the film dosimetry process, 
which has a calibration component and a measurement component. Also, the calibration is done 
to the film in the solid medium, but not to the solid medium itself, and the eye plaque measurements 
are again reading dose to film in the solid medium, not dose to the solid medium. I hypothesized 
that since film calibrations and film dosimetry measurements both are done in Solid Water, while 
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the calibration dose data is known in liquid water, the results of the film dosimetry are doses in 
liquid water without the need for additional corrections. This hypothesis was rigorously tested 
utilizing the second prototype of the novel 125I eye plaque using Monte Carlo simulations by Dr. 
Munro, the inventor of the novel 125I eye plaque. He extensively used Monte Carlo simulations in 
the invention process. Therefore, the eye plaque and calibration seed modeling were already in 
place as per specifications provided by Implant Sciences Corporation. The author has supplied our 
phantom and film geometrical drawings and elemental compositions to be used as input data, based 
on specifications provided by Gammex, Inc. and International Specialty Products respectively. 
The author defined the required simulations and analyzed the Monte Carlo results. We already had 
film calibration and dosimetric results of the second prototype eye plaque done using film in Solid 
Water with the film calibrated using seed dosimetric data in liquid water. Therefore, the I-Plant 
model 3500 calibration seed data was converted using Monte Carlo to data in Solid Water, instead 
of liquid water. Then we created new film calibration curves in terms of doses to film in Solid 
Water. Then all eye plaque measurements were re-calculated using these calibration curves and 
the result was eye plaque data in terms of dose to film in Solid Water. Then the eye plaque results 
were converted using Monte Carlo to doses in liquid water needed for comparison with our original 
uncorrected results in order to test the hypothesis. 
The materials and methods employed by Dr. Munro in this analysis were similar to those employed 
in the Monte Carlo analysis of the Model 3500 seed147. Radiation transport calculations were 
performed on a Windows (Microsoft Corporation, Redmond, WA) based personal computer 
running the MCNP5 Monte Carlo computer code148 (Los Alamos National Laboratory, Los 
Alamos, NM). The software was used to simulate coupled photon and electron transport through 
material using the MCPLIB04 photo-atomic cross-section tables provided with the MCNP5 code.  
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These cross section tables are derived from the EPDL97 dataset149, and offer superior 
representation of low energy photoelectric interactions in low Z materials relative to previous 
EPDL datasets150-152. Simulations were performed in water, Solid Water, and radiochromic film 










30.955 0.130    
31.704 0.0375  
35.493 0.0668 




Table 3. 125I source photons used in the Monte Carlo model.  Source photons with energies less 
than 5 keV, and source electrons, were ignored due to their relatively low yields and negligible 




The 125I photon spectrum was characterized as 6 photons with energies and abundances obtained 
from the Brookhaven National Laboratory web site153 and which emanate isotropically from 
positions within the active, ion implanted, layer of the seed core or plaque substrate. The 125I 
photon spectrum used in this investigation is listed in Table 3. 
 A complete description of the Monte Carlo methodology used is provided by Medich et al154. 
The uncertainty in the overall results is estimated to be less than 3%, largely due to uncertainties 
in cross section values, using methodology described by Medich et al155. 
2.9.1 Seed calibration geometry. 
The   125I I-Plant model 3500 brachytherapy seed used for the EBT film calibration was modeled 
in liquid water. The dose rate in terms of cGy/hour-U was calculated along straight lines 
perpendicular to the seed long axis in the center planes of each active layer at the expected position 
of the calibration film in the Solid Water phantom (i.e., the film plane parallel to the seed plane at 
a distance 6.71 mm between the mid-plane of the active layers and the center of the seed long 
axis). Along these straight lines are the profiles used to create the calibration curve of the film, 
described in the film calibration section. A cross section of EBT film shown in Figure 25 of the 
Radiochromic film section can help one to understand the geometry. 
The dose rate used for all calculations was the average between the dose rates to the upper active 
layer of the film and the lower active layer of the film, while the mid-plane of the film was used 
for all coordinates on the film. The next step was to replace the liquid water with the Solid Water 
phantom in the seed calibration geometry described in the film calibration section 2.6.2, and to 
repeat the Monte Carlo simulations. The ratio of the dose rate to film in Solid Water to the dose 
rate to film in liquid water was first averaged between equidistant points from the center of the 
film, then fitted with a 5th degree polynomial using CurveExpert Professional software (Daniel G. 
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Hyams, Madison, AL) and used to multiply each point of the calibration curve created as described 
in the film calibration section 2.6.2, resulting in a calibration curve for dose to film in Solid Water. 
Re-evaluation of films measured with the second prototype eye plaque was done using the latter 
calibration curve, resulting in doses to film in Solid Water, which were later converted to doses to 
liquid water using Monte Carlo simulations as explained in next section. In order to better 
understand the order of magnitude and importance of this correction, we tested if results would 
differ if the film was replaced by Solid Water, i.e., how important it is to model the actual film 
used as opposed to just using a ratio of dose to Solid Water to dose to liquid water. The Solid 
Water used in this work contains 2.3% calcium, but we also tested the dose to Solid Water with 
1.7% calcium content, both of which were discussed by Meigooni et al135. 
2.9.2 Eye plaque geometry. 
The second prototype eye plaque was first modeled in liquid water and then in Solid Water, in the 
“eye” phantom inserted into the full scatter 30 cm x 30 cm x 30 cm phantom, as described in the 
Solid Water “eye” phantom section. The dose rates in cGy/hour-mCi were calculated on the central 
axis of the plaque (axis perpendicular to the center of the inner concave surface of the plaque, 
which is facing the eye) every 0.25 mm, starting 0.25 mm from the surface of the plaque to 12.50 
mm from the surface of the plaque. For the depth dose rate simulations in Solid Water, an EBT 
film was modeled at each location, thus the dose rate to film in Solid Water was calculated. At 
each depth the dose rates were averaged over a circular area with a radius of 0.5 mm. A similar 
circular area was used to evaluate the doses at the centers of the irradiated films in the Contour 
program. The dose rates in liquid water normalized to 3 mm from the plaque’s inner surface were 
used for comparison with the depth dose rates measured on films. The ratio of the central axis dose 
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rates to film in Solid Water to the dose rates to liquid water was used to convert the dose rates 
measured on the central axis of the films from doses to film in Solid Water to doses to liquid water. 
Then, dose rates were calculated in liquid water for each film position perpendicular to the central 
axis of the plaque in terms of dose rates to circular annuli with radii increasing by 0.1 mm, starting 
with a 0.05 mm circle, the next annulus between radii 0.05 mm and 0.15 mm, and so on until the 
radius of the actual film for small films which fitted inside the eye plaque or the radius 12.95 mm 
for the large films below the eye plaque was reached. Then the simulations were repeated for films 
modeled in Solid Water at the same locations. The ratios of dose rates to film in Solid Water to 
dose rates to liquid water were used to convert the dose rates measured in Solid Water to dose rates 
in liquid water. We did not convert the full 2D dose map derived from the planar films in Solid 
water to 2D dose maps in liquid water, but rather converted selected profiles in the films. If the 
results were to be used for treatment planning, a full conversion of the film data to liquid water 
would be possible using this method. 
3. Eye plaque dosimetry results and discussion. 
3.1 106Ru eye plaques. 
The accurate dosimetry methods, techniques and results as applied to 106Ru eye plaques are 
described in the published article42 which is attached as Appendix 1. Partial results of 106Ru eye 
plaques dosimetry were also presented at a number of national and international meetings75-77, 82, 
83 and the author contributed his accumulated experience as a co-author of the ISO International 
Standard 21439:2009: Clinical Dosimetry – Beta Radiation Sources for Brachytherapy41. 
In addition to published 106Ru eye plaque findings, below are results of interest not shown in the 
published article42. Eight different 106Ru eye plaques belonging to three types (CCX, CCA and 
CIA) were dosimetrically characterized in this thesis. The first plaque characterized in this work 
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was CCX 36. The dosimetric measurements of this plaque were done using the NIST phantom 
provided to us by Dr. Soares and shown in Figure 14. Working on the dosimetric characterization 
of this eye plaque started our learning curve in dealing with radiochromic film dosimetry, which 
included film handling, scanning and calibration protocols developed in this work and published 
in its process42, 113. The remaining six plaques: CCX 41, CCX 55, CCX 104, CCX 129, CCX 219, 
CCA 892, and CIA 156 were characterized using the Solid Water “eye” phantom designed in the 
course of this work.  
The measurements of the CCX 36 eye plaque were done using GAFCHROMIC MD-55-2 film 
belonging to Lot #37350, irradiating one film at a time to an approximate dose of 30 Gy at the 
center of the film. Eight films were irradiated at distances ranging from 0.70 mm to 10.14 mm 
from the middle of the film to the inner surface of the plaque. Films at depths 2.62 mm and 3.21 
mm were repeated to test the reproducibility and the results were within 1.30% and 12.0% of each 
other, respectively. These measurements were done before we established the technique of cutting 
the batch of film into more uniform sub-batches, described in section 1.4 of the Introduction.  The 
films were calibrated using a 60Co teletherapy machine as recommended for electron dosimetry by 
TG-5598. The dose rate measured along the central axis of the CCX 36 plaque is shown in Figure 
41. The film results were fitted using a Gaussian Model analytical fit using CurveExpert 
Professional: 








Figure 41. Dose rate measured along the central axis of the CCX 36 plaque along with a fitted 
analytical curve and the data provided by BEBIG. 
 
The BEBIG uncertainty reflected in the error bars was the stated ±30% (k=2), while our 
measurement uncertainty for this type film was 11.5% (k=2), somewhat larger than the 8.6% (k=2) 
uncertainty determined for later EBT types of film42. The increase in uncertainty reflected a 4% 
film non-uniformity in the uncertainty calculation vs. 1.5% for EBT type films. The measured dose 
rate was substantially higher than the dose rate provided by BEBIG, as discussed in the 
Introduction section and in the published article42, which shows in Figure 7 the results of CCX 55 
eye plaque measured using film and a semiconductor diode, as well as a comparison of our 
measurements with NIST results shown in Table 1. A planar dose distribution of the CCX 36 
plaque is shown in Figure 42. There is a 16.6% hot spot centered approximately 3.5 mm from the 






























Figure 42. Dose rate in a plane perpendicular to the central axis of the CCX 36 plaque at depth 
3.21 mm from the plaque. View from the plaque. 0.5 cm between grid lines. 
 
 




During measurements in the NIST phantom it was found that it is very difficult to control the film 
rotation vs. the eye plaque, since the phantom had no co-registration features. The marks on the 
film seen in Figure 42 were helpful for controlling the film’s direction of polarization for proper 
scanning purposes, but not co-registration with the eye plaque. Therefore a setup image of the 
plaque obtained by simply placing it on film and allowing it to irradiate the film for some time is 
shown in Figure 43. Even though this image shows isodose lines, these have no dosimetric 
meaning, except to show the approximate location of the dosimetric non-uniformity vs. the 
plaque’s suture lugs.  
Of special interest is the CCX 41 plaque which was only briefly mentioned in the published 
article42. This plaque was delivered by BEBIG to Dr. Soares at NIST in order to calibrate BEBIG’s 
dosimetry. The calibration process started with NIST calibrating the eye plaque twice using 
calibrated HD-810 GAFCHROMIC film and the NIST phantom shown in Figure 14, as well as 
two calibrated scintillation detectors. The films and the plastic scintillation detectors were 
calibrated using the same calibrated 90Sr/90Y ophthalmic applicator. The results of the four sets of 
measurements were fitted with an analytical function and the whole process and results were 
detailed in the NIST Calibration Report156. Then NIST was supposed to return the eye plaque to 
BEBIG with the Calibration Report156 and BEBIG was supposed to use the eye plaque as their 
standard for calibration of their plastic scintillators used for dosimetry in the production of eye 
plaques. In this particular case we borrowed the eye plaque after the NIST calibration prior to its 
return to BEBIG by NIST and performed a full set of film measurements in our “eye” plaque 
phantom using MD-55-2 film belonging to Lot #I1215. Sheets 2 and 3 of the lot were cut into 3 
cm wide strips in order to use more uniform film in accordance with our previously described 
technique and the strip marked as 2 from both sheets was used. The film was calibrated using 
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MSKCC’s 60Co teletherapy machine. The full set of dose distributions of our measurements is 
shown in Figures 44a – 44h below. This is the only full set of measurement results shown in this 
dissertation, done in order to present a full set of film results. 
 
 
Figure 44a. Dose rate in a plane perpendicular to the central axis of the CCX 41 plaque at depth 
1.835 mm from the plaque. View from the plaque. 0.5 cm between grid lines. 
 
 
Figure 44b. Dose rate in a plane perpendicular to the central axis of the CCX 41 plaque at depth 




Figure 44c. Dose rate in a plane perpendicular to the central axis of the CCX 41 plaque at depth 
3.445 mm from the plaque. View from the plaque. 0.5 cm between grid lines. 
 
 
Figure 44d. Dose rate in a plane perpendicular to the central axis of the CCX 41 plaque at depth 





Figure 44e. Dose rate in a plane perpendicular to the central axis of the CCX 41 plaque at depth 
4.475 mm from the plaque. View from the plaque. 0.5 cm between grid lines. 
 
 
Figure 44f. Dose rate in a plane perpendicular to the central axis of the CCX 41 plaque at depth 




Figure 44g. Dose rate in a plane perpendicular to the central axis of the CCX 41 plaque at depth 
6.435 mm from the plaque. View from the plaque. 0.5 cm between grid lines. 
 
 
Figure 44h. Dose rate in a plane perpendicular to the central axis of the CCX 41 plaque at depth 
7.445 mm from the plaque. View from the plaque. 0.5 cm between grid lines. 
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The agreement between repeat films is within 5.3%. The dose rate measured along the central axis 
of the plaque along with the fitted curve of the NIST measurements156 is shown in Figure 45. 
 
Figure 45. Dose rate measured along the central axis of the CCX 41 plaque compared to the NIST 
Calibration Report fitted curve156. 
 
Cross comparisons of this kind are the gold standard of dosimetric measurements and are 
performed on a routine basis between NIST, national standard laboratories of other countries and 
accredited dosimetry calibration laboratories in the U.S. Our results agreed to within 8% with the 
NIST report, which is good agreement for this kind of measurement73 and within accepted 
combined uncertainties (k=1) for radiochromic dosimetry of ophthalmic brachytherapy sources41, 
113. The combined expanded uncertainty of the NIST measurement is 15% (k=2)156 and the 
estimated combined expanded uncertainty of our measurement is 11.5% (k=2) using MD-55-2 































from Memorial Sloan-Kettering Cancer Center as the “gold standard” for testing his liquid 
scintillation method. This project resulted in a meeting presentation and publication78, 157, which 
included our results. Since this was the only published data on CCX plaques dosimetry until 
recently, it was used by Hermida-López for comparison with his Monte Carlo simulations of 106Ru 
eye plaques79. 
A 2D treatment planning program enabling one to account for dosimetric non-uniformities of 106Ru 
eye plaques, which can result in hot and cold spots in the treated eye, was developed at MSKCC 
using the film measured data, and is briefly described in the published article42. The program 
calculates for any depth and lateral distance from the central axis minimum and maximum doses 
in the form of isodose lines as shown in Figure 46.  
 
Figure 46. Minimum isodose lines in cGy/hour of a 106Ru eye plaque calculated from film 
measurements. The vertical axis is distance along the central axis of the plaque in mm; the 
horizontal axis is lateral distance from the central axis in cm. 
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These isodose lines then can be superimposed on the ultrasound image of the tumor as shown in 
Figure 47 enabling one to account for overdosing critical structures by the maximum doses or 




Figure 47. Minimum isodose lines of a 106Ru eye plaque superimposed on an ultrasound image of 
an ophthalmic tumor. 
 
3.2 Novel 125I eye plaque and collimator. 
3.2.1 First prototype eye plaque. 
The film dosimetry of the first prototype eye plaque was done using XR-T film Lot # K02b28XRT 
as detailed in the Radiochromic film section 2.3, using the head phantom setup described in the 
Solid Water “eye” phantom section 2.2. Two films were irradiated at distances 2.9 mm and 10.79 
mm from the inner surface of the plaque. Unfortunately the work on the first prototype had to be 
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stopped after these two films, since we discovered a minor degree of radioactive contamination 
that was traced to encapsulation problems. Each film was scanned 7 days after the end of 
irradiation using the Vidar VXR 16 Dosimetry Pro 16 bit film scanner at 89µm resolution, driven 
by RIT film dosimetry software. The films were scanned in clear sheet protectors together with a 
red acetate filter exactly like the calibration film as described in sections 2.5 and 2.6.2. 
The dose rate distribution measured using a film perpendicular to the central axis of the plaque at 
the distance 10.79 mm from its inner surface is shown in Figure 48. The dose rate along the central 
axis of the plaque measured using the Scanditronix stereotactic diode in a water tank, as described 
in section 2.8, together with a fitted analytical curve and superimposed film results, are shown in 




Figure 48. Dose rate distribution at the distance 10.79 mm from the inner surface of the first 




Figure 49. Dose rate on the central axis of the first prototype plaque measured using the 
Scanditronix stereotactic diode along with a fitted analytical curve and both film measurements. 
 
The curve was fitted using CurveExpert Professional software by a rational function 
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 where a, b, c, and d are the fit parameters and x is the distance from the inner surface of the plaque 
along the central axis. The fitted function provides the dose rate at any point along the central axis 
of the plaque. The dose rate at the center of the 2.90 mm film was found to be 7.7% higher than 
the dose rate measured at the same distance using the Scanditronix stereotactic diode in the water 
tank, while the dose rate at the center of the 10.79 mm film was found to be 6.5% higher than the 
































radiochromic film dosimetry and is within the accepted combined uncertainties (k=1) for 
radiochromic film dosimetry of ophthalmic and low energy photon brachytherapy sources41, 113. It 
should be noted that the results of the semiconductor diode calibrated using a calibrated 125I 
brachytherapy seed were in good agreement with film dosimetry results, even though, per the diode 
manufacturer’s specifications, it is rated for energies above 1 MeV. 
Water tank scans across the plaque in a plane including its central axis using the Scanditronix 
stereotactic diode at three different distances from the plaque’s inner surface are shown in Figure 
50. The distances were measured along the central axis of the plaque. These scans were done using 
the uncalibrated electrometer of the water tank and therefore are considered relative only. 
 
Figure 50. Water tank scans across the plaque at three different distances from the inner surface 































The results of the film dosimetry for both films, as can be seen in the film shown in Figure 48, as 
well as the water tank scans shown in Figure 50, demonstrate highly symmetrical dose distributions 
around the central axis and do not exhibit any hot or cold spots. 
The dose rate on the central axis 6.0 mm from the plaque’s inner surface (5.0 mm from the inner 
sclera, which is the standard COMS prescription point for tumors not higher than 5.0 mm) is 163.2 
cGy/hour. The dose rates recommended by the American Brachytherapy Society are 60 – 105 
cGy/hour at the tumor apex96. In the first prototype eye plaque, these dose rates are achieved for 
tumors with apical heights of 7 - 10 mm and thus, the dose rates are clinically relevant. Changing 
the activity of the manufactured plaque would enable customization of the dose rate to the apical 
height of the tumor to be treated. 
3.2.2 Second prototype eye plaque. 
Film dosimetry of the second prototype eye plaque was done using EBT film Lot # 34351-05 as 
described in the Radiochromic film section 2.3 using the full scatter phantom setup described in 
the Solid Water “eye” phantom section 2.2. Films were irradiated without the collimator in 9 planes 
perpendicular to the central axis of the plaque at distances ranging from 0.96 to 12.33 mm from 
the inner surface of the plaque. In addition, four films with the collimator were irradiated at 
distances 0.24, 1.09, 2.83, and 5.48 mm from the inner surface of the plaque. The film at the 
distance 0.24 mm was a curved film attached to the surface of the collimator. All films were 
scanned 24 hours after the end of the irradiation using the Epson Expression 1680 flatbed scanner 
in 48 bit color mode, followed by the extraction of the red channel. A portion of the films were 
scanned again 48 hours after the end of the irradiation in order to access post-exposure growth 
during the second 24 hours after irradiation. As usual a number of films were exposed at the same 
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depth in order to access measurement reproducibility. Dosimetric results of the replicate films were 
within 0.9% of each other, which is indicative of the uncertainty of the measurements. 
Film analysis was done using MSKCC’s film dosimetry Contour program. First, all scanned films 
were converted from pixel values to dose to liquid water using the uncorrected calibration curve 
created by irradiating the calibration film in Solid Water, but using the seed TG 4353 data, which 
provides dose to liquid water. Then, the films without the collimator were converted again from 
pixel values to dose to film in Solid Water using the Monte Carlo corrected calibration curve as 
described in the Seed calibration geometry sub-section 2.9.1 of the Monte Carlo simulations of the 
novel 125I eye plaque dosimetry section 2.9. The latter results were converted again using Monte 
Carlo conversion factors from dose to film in Solid Water to dose to liquid water, which were 
deemed the correct results of the eye plaque dosimetry. The results with the uncorrected calibration 
curve were compared to the Monte Carlo corrected results in order to assess the level of precision 
added by the Monte Carlo correction, or the uncertainty introduced by lack of correction. The films 
with the collimator were not corrected using Monte Carlo, i.e., the second prototype eye plaque 
was not modeled in Monte Carlo with the collimator for this dosimetric analysis. The role of the 
films with the collimator was limited to assessment of the existence of hot and cold spots due to 
the collimator and to assessment of the effect of the collimator on dose rate. 
A typical example of a dose rate distribution measured using film is shown in Figure 51. The film 
was located 5.35 mm from the inner surface of the plaque. A horizontal profile across the center 
of the film in Figure 51 is shown in Figure 52. The profile is shown in three versions, as described 
above: 1) uncorrected dose rate to water (measurement done in Solid Water, but calibration done 
using TG-4353 parameters in liquid water), 2) dose rate to film in Solid Water, and 3) dose rate to 





Figure 51. Dose rate distribution at distance 5.35 mm from the inner surface of the plaque. View 
from the plaque. 0.5 cm between grid lines. 
 
It is clearly seen from the profiles in Figure 52, as well as from the planar films, such as the one 
shown in Figure 51, that the second prototype eye plaque has a radially isotropic dose distribution 
without hot and cold spots, similar to that exhibited by the first prototype eye plaque. It is possible 
to conclude from both prototypes that the eye plaque manufacturing process results in eye plaques 
with uniform distribution of 125I. 
The dose rate along the central axis of the plaque measured using radiochromic film (uncorrected 
results) along with the Monte Carlo simulated dose rate in liquid water along the central axis are 
shown in Figure 53. Both curves were normalized at 3.0 mm from the inner surface, since the 
Monte Carlo simulation does not provide the absolute dose rate of the eye plaque. For the 
normalization purpose the film CAX dose rate was fitted with an analytical curve (not shown in 
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Figure 53). It can be seen that the dose rate measured using film is in good agreement with the 





Figure 52. Three versions of a horizontal profile through the central axis of the film at a distance 
5.35 mm from the inner surface of the plaque: 1) uncorrected dose rate to water (measurement 
done in Solid Water, but calibration done using TG-4353 seed parameters in liquid water), 2) dose 
rate to film in Solid Water, and 3) dose rate to film in Solid Water converted to dose rate in liquid 
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Figure 53. Relative dose rate on the central axis (CAX) of the second prototype plaque measured 
using radiochromic film along with the Monte Carlo simulated relative dose rate. Both curves are 
normalized at a distance 3.0 mm from the inner surface of the plaque. 
 
Figure 54 depicts the uncorrected absolute dose rate to liquid water along the central axis of the 
plaque measured using radiochromic film (measurement done in Solid Water, but calibration done 
using TG-4353 parameters for liquid water) together with the superimposed dose rate to film in 
Solid Water converted to dose rate in liquid water along with a fitted analytical curve of the dose 
rate to film in Solid Water converted to dose rate in liquid water. The curve has been fitted using 
a reciprocal quadratic function  
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where a, b, and c are fit parameters and x is the distance from the inner surface of the plaque along 
the central axis. The fitted function enables one to calculate the dose rate at any point along the 
central axis of the plaque. 
 
Figure 54. Uncorrected absolute dose rate on the central axis of the plaque with superimposed 
dose rate to film in Solid Water converted to dose rate in liquid water along with a fitted analytical 
curve of the dose rate to film in Solid Water converted to dose rate to in liquid water. 
 
The results shown in Figures 52 and 54 indicate, at least for EBT film in Solid Water 2.3 (Solid 
Water with 2.3% calcium content), the uncorrected method (all calibrations and measurements 
done in Solid Water using TG-4353 parameters in liquid water for calibration) produces very 
similar results to the same measurements corrected and converted using Monte Carlo simulations. 
The actual ratio between the results varies between 0.989 and 1.024 (average 1.0075 ± 0.0096 std. 
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simulations employed. This finding supports the hypothesis presented in section 2.9, at least for 
this particular case, namely that when calibrations and measurements are done in the same kind of 
Solid Water phantoms, while using calibration doses defined in liquid water, the final result is dose 
in liquid water. This conclusion, however, should be tested for each phantom/film combination. 
The dose rate on the central axis 6.0 mm from the plaque’s inner surface (5.0 mm from the inner 
sclera) is 40.8 cGy/hour. It should be noted although this value is below the clinical dose rate range 
recommended by the American Brachytherapy Society96, the activity of the second prototype was 
four times weaker than of the first prototype at the time of dosimetric measurements. 
Partial results of the dosimetric analysis of the second prototype of the novel 125I eye plaque were 
presented at an annual meeting of the American Association of Physicists in Medicine158.  
3.2.3 Monte Carlo corrections. 
The dose rates of the calibration 125I I-Plant model 3500 seed in terms of cGy/hour-U to liquid 
water, and to EBT film in Solid Water, calculated using Monte Carlo are shown in Figure 55. The 
dose rates are calculated in the midplane of the film or in liquid water at the coordinate where the 
midplane of the film would be, along a profile crossing the center of the seed perpendicular to the 
seed long axis. The ratio of the dose rates shown in Figure 55 averaged between the “left” and 
“right” sides of the seed along with a curve fitted using a 5th degree polynomial is shown in Figure 
56. The fitted ratio was used to multiply each point of the uncorrected calibration curve as 
explained in section 2.9.1 and obtain a film calibration curve of dose to EBT film in Solid Water. 
The eye plaque results obtained using this corrected calibration curve were converted to dose in 
liquid water using Monte Carlo as explained in section 2.9.2 and one such profile is shown in 
Figure 52. These calculations and conversions were done for all films at all measurement depths. 






Figure 55. Dose rate along a profile perpendicular to the calibration seed long axis crossing the 
seed center in the midplane of EBT calibration film in Solid Water, and the dose rate in liquid 
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Figure 56. Ratio of dose rate to EBT film in Solid Water to dose rate in liquid water together with 
an analytical fit. 
 
In order to better understand the behavior of the Monte Carlo corrections, the seed geometry was 
modeled in two types of Solid Water with and without film at the calibration film depth of 6.71 
mm. The elemental composition of both types of Solid Water is given in Table 4 and of both types 
of film in Table 5. The Solid Water used in this work has 2.3% calcium content and is similar to 
what Meigooni et al135 called Solid Water 2.3. We used our exact composition and called it the 
same name. The Solid Water with 1.7% calcium content used for our Monte Carlo simulations has 
the exact composition of the Solid Water 1.7 cited by Meigooni et al135. The elemental 
compositions of the active layers of EBT and EBT3 film and of the clear polyester which is part 
















































Distance from calibration seed film center (mm)











Hydrogen 8.2% 8.4% 
Carbon 68.0% 69.0% 
Nitrogen 2.4% 2.0% 
Oxygen 19.6% 18.3% 
Chlorine 0.1% 0.0% 
Calcium 1.7% 2.3% 
Density of the Solid Water 1.036 1.044 
 
Table 4. Elemental composition and densities of Solid Water 2.3 and Solid Water 1.7 used for 












Hydrogen (H) 9.4 8.64 4.20 
Lithium (Li) 0.8 0.63  
Carbon (C) 57.4 49.91 62.50 
Nitrogen (N) 13.2 0.64  
Oxygen (O) 16.4 32.27 33.30 
Sodium (Na)  0.35  
Aluminum (Al)  6.55  
Sulfur (S)  0.49  
Chlorine (Cl) 2.8 0.54  
Total 100 100 100 
 
 






Ratio of dose 
rate to EBT 
film in Solid 
Water 2.3 to 
dose rate to 
liquid water 
Ratio of dose 
rate to Solid 
Water 2.3 to 
dose rate to 
liquid water 
Ratio of dose 
rate to EBT 
film in Solid 
Water 1.7 to 
dose rate to 
liquid water 
Ratio of dose 
rate to Solid 
Water 1.7 to 
dose rate to 
liquid water 
0.0 0.907 1.039 0.923 0.941 
1.0 0.905 1.037 0.923 0.941 
2.0 0.903 1.034 0.923 0.942 
3.0 0.901 1.032 0.923 0.942 
4.0 0.899 1.030 0.924 0.942 
5.0 0.897 1.027 0.924 0.943 
6.0 0,895 1.025 0.924 0.943 
7.0 0.893 1.022 0.925 0.943 
8.0 0.891 1.020 0.925 0.944 
9.0 0.889 1.018 0.925 0.944 
10.0 0.887 1.015 0.925 0.944 
11.0 0.885 1.013 0.926 0.945 
12.0 0.883 1.010 0.926 0.945 
Average ratio 0.895 1.025 0.924 0.943 
 
 
Table 6. Ratios of dose rate to EBT film in two types of Solid Water to dose rate in liquid water, 
and ratios of dose rates in two types of Solid Water at film’s location, but without the film to dose 






Ratio of dose 
rate to EBT3 
film in Solid 
Water 2.3 to 
dose rate to 
liquid water 
Ratio of dose 
rate to Solid 
Water 2.3 to 
dose rate to 
liquid water 
Ratio of dose 
rate to EBT3 
film in Solid 
Water 1.7 to 
dose rate to 
liquid water 
Ratio of dose 
rate to Solid 
Water 1.7 to 
dose rate to 
liquid water 
0.0 1.077 1.039 1.097 0.941 
1.0 1.076 1.037 1.098 0.941 
2.0 1.074 1.034 1.099 0.942 
3.0 1.072 1.032 1.100 0.942 
4.0 1.071 1.030 1.100 0.942 
5.0 1.069 1.027 1.101 0.943 
6.0 1.067 1.025 1.102 0.943 
7.0 1.065 1.022 1.103 0.943 
8.0 1.064 1.020 1.103 0.944 
9.0 1.062 1.018 1.104 0.944 
10.0 1.060 1.015 1.105 0.944 
11.0 1.059 1.013 1.106 0.945 
12.0 1.057 1.010 1.106 0.945 
Average ratio 1.067 1.025 1.102 0.943 
 
Table 7. Ratios of dose rate to EBT3 film in two types of Solid Water to dose rate in liquid water, 
and ratios of dose rates in two types of Solid Water at film’s location, but without the film to dose 
rate in liquid water. 
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The results of the Monte Carlo simulations for all four conditions for EBT film – ratios of dose 
rates to film in Solid Water to dose rates in liquid water, and dose rates in Solid Water at the 
location of the film, but without film, to dose rates in liquid water are given in Table 6, while the 
same ratios for EBT3 film are given in Table 7. 
It can be seen that both the calcium content and the film composition strongly influence the results. 
In the case of Solid Water 2.3 the ratio decreases by 2.7% when moving from the central axis to 
the 12.0 mm lateral distance with EBT film, and decreases by 2.8% without the film. This result 
can be considered constant within the uncertainties with and without film, but the ratio itself with 
film is on average 12.7% lower than without film. In the case of Solid Water 1.7, the ratio increases 
by 0.4% with and without EBT film, again constant within the uncertainties. The ratio itself with 
film is, however, on average 2.0% lower than without film. In both cases, the ratio with film is 
lower than the ratio without, and notably much lower when using Solid Water 2.3, which seems to 
be the prevalent type delivered by the manufacturer. For EBT3 film in the case of Solid Water 2.3 
the ratio decreases by 1.9% when moving from the central axis to the 12.0 mm lateral distance 
with EBT3 film and decreases by 2.8% without the film. While this finding can be considered 
constant within the uncertainties with and without film, the ratio itself with film is on the average 
4.1% higher than without film. In the case of Solid Water 1.7, the ratio increases by 0.8% with 
film and by 0.4% without film, again almost constant within the uncertainties, but the ratio itself 
with film is on the average 16.8% higher than without film. Therefore it is very important to have 
the exact elemental composition of the Solid Water used for low-energy photon dosimetry, as well 
as to model the geometry with the film used. The literature concerning Monte Carlo derived 
differences between solid media and liquid water132-135, already noted in the Introduction focused 
only on dose differences between these two types of media, but did not look into dose to the 
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dosimeter used in solid media and its conversion to dose to liquid water, which is film in our case. 
Dose to the film can be as much as 16.8% different then dose to the solid media without film. The 
large difference between the EBT and EBT3 films ratios could possibly be explained by the 
difference between the mass energy absorption coefficients (µen/ρ) vs. liquid water shown in Figure 
57, which were calculated using the mass energy absorption coefficients of the elements159. The 




Figure 57. Mass absorption coefficients of water, EBT and EBT3 films. 
 
In order to convert the eye plaque results from dose to EBT film in Solid Water to dose in liquid 
water for measurements on the central axis, a Monte Carlo simulation was performed both in liquid 
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water and in EBT film in Solid Water. Calculations were made at 0.25 mm intervals along the 
central axis of the plaque and at each of the 9 planar films, as explained in the Eye plaque geometry 
sub-section 2.9.2 of Monte Carlo simulations of the novel 125I plaque dosimetry section 2.9.  
The ratio of dose to liquid water to dose to EBT film in Solid Water along the central axis of the 
plaque has been fitted with a linear fit: y=a+bx, using CurveExpert Professional software, where 
y is the ratio, and x is the coordinate along the central axis of the plaque, a and b are the fit 
parameters. This ratio increases with depth from 1.092 at 0.25 mm depth to 1.122 at 12.5 mm 
depth for a total change of 3.0%. It was used to convert the film measurements from dose to EBT 
film in Solid Water to dose to liquid water. The uncorrected and corrected results for the measured 
dose rate along the central axis are shown in Figure 54 and were already discussed.  
The off-axis ratios of dose to liquid water to dose to EBT films in Solid Water for 5 out of the 9 
film planes are shown in Figure 58. 
These off-axis ratios were used to convert profiles across films from dose rate to EBT film in Solid 
Water to dose rates to liquid water. One such example is shown in Figure 52. Again, the 
uncorrected and corrected results are in very close agreement, even despite clear trends seen in 
Figure 58. In the example shown in Figure 52 at the depth 5.35 mm, the average ratio between 
uncorrected and corrected profiles is 1.018 with a standard deviation of 0.011. It seems that these 
trends just offset the conversion trends introduced by the film calibration curve, when converting 
the measured results to dose to EBT film in Solid Water. And, as already said, it can be concluded 
that at least for EBT film in Solid Water 2.3, the uncorrected method (all calibrations and 
measurements done in Solid Water using TG-4353 parameters for liquid water for calibration) 





Figure 58. Off-axis ratios of dose rate to liquid water to dose rate to EBT films in Solid Water at 
5 planar films perpendicular to the central axis of the plaque at different distances from the inner 
surface of the plaque. 
 
3.2.4 Collimator dosimetry. 
The dose rate distributions produced by the collimator described in the Novel 125I eye plaque and 
collimator section 2.1.3 at distances 0.24 mm (surface of the plaque), 1.09 mm (inner sclera), and 
2.83 mm, are shown in Figures 59, 60, and 61. The dose rate at 5.48 mm from the plaque was too 























































Figure 59. Dose rate distribution at the distance 0.24 mm from the inner surface of the plaque. 
The film is attached to the curved surface of the collimator. View from the plaque. 0.5 mm grid. 




Figure 60. Dose rate distribution at the distance 1.09 mm from the inner surface of the plaque. 




Figure 61. Dose rate distribution at the distance 2.83 mm from the inner surface of the plaque. 
View from the plaque. 1.0 mm grid. Dose rate at CAX 1.5 cGy/hour. 
 
Vertical profiles through the central axis of the films shown in Figures 59, 60, and 61 are shown 
in Figure 62. It can be seen from the dose rate distributions and profiles, especially the profile at 
the level of the inner sclera, that the collimator does not produce hot and cold spots. The collimated 
dose rate at 1.09 mm is 20.1 times weaker, and at 2.83 mm is 55.3 times weaker, than un-collimated 
dose rates, since only a very small area of the eye plaque contributes to the collimated dose rate. 
The total area of the 128 holes was about 1 mm2 vs. 276 mm2 total inner surface of the plaque. 
Further from the plaque’s surface the contribution of the total inner surface to the uncollimated 
dose rate is much larger, hence the much stronger attenuation 2.83 mm from the plaque as 
compared to 1.09 mm. 
A 3D treatment plan would consist of a number of collimated fields, and the plaque could have 
much higher activity than the second prototype, but this could still produce insufficient dose rates, 
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especially for larger tumors. The divergence of the collimated fields seen in Figures 59 - 62 needs 
further investigation, as it could become a limiting factor in creation of clinical treatment plans. 
 
Figure 62. Vertical profiles through the central axis of the 0.24 mm, 1.09 mm, and 2.83 mm films. 
 
3.3 Fully loaded 20 mm COMS plaque. 
Film dosimetry was done at 16 planes perpendicular to the central axis of the plaque at distances 
ranging from 0.0115 mm to 19.10 mm from the inner surface of the plaque, corresponding to the 
distance to the outer sclera, using the special thin EBT1 film Lot 35314-4H in the Solid Water 
“eye” phantom placed at the center of a 30 cm x 30 cm x 30 cm full scatter phantom. A calibrated 
Model 6711 125I seed (Oncura, Inc., Arlington Heights, IL) and the TG-4353 formalism were used 
for film calibration. All results are presented in terms of dose rate per unit air kerma strength per 


























Distance along collimator profile in film plane (mm)
2.83 mm
1.09 mm - inner sclera
0.24 mm - outer sclera
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The comparison between the measured dose rate on the central axis of the plaque and the dose rate 
calculated using BrachyDose Monte Carlo calculations54 using the assumption of heterogeneous 
geometry, which includes the Silastic insert and the gold alloy (Modulay) backing, is shown in 
Figure 63. The measured curve was obtained using uncorrected film data, which are based on film 
calibration in Solid Water with TG-4353 parameters for liquid water. In the case of 2.3% calcium 
Solid Water combined with EBT film, the uncorrected results are in close agreement with Monte 
Carlo corrected results, well within measurement and Monte Carlo uncertainties, as was shown in 
the case of the novel 125I eye plaque discussed in sub-section 3.2.2. Therefore, Monte Carlo 
corrections were not needed. Measured depth dose on the central axis agrees well with the results 
of Monte Carlo calculations. The point by point average ratio of the fitted measurements curve to 
the Monte Carlo fitted curve is 0.971 ± 0.027 std. dev. These results validate the BrachyDose 
Monte Carlo simulations concerning the dose reduction effect of the plaque’s backing and insert54. 
As per the BrachyDose Monte Carlo results presented in TG-12940, the plaque’s dose rate on the 
central axis is on the average about 15% lower than predicted by homogenous TG-4353 calculations 
(average ratio between heterogeneous to homogenous calculation is 0.853 ± 0.017 std. dev.). 
Uncorrected (homogenous) and corrected (heterogeneous) central axis dose rates calculated using 
the Plaque Simulator software are presented in Figure 63 as well. It can be seen that the corrected 
dose rate is in good agreement with the BrachyDose Monte Carlo and the measurements of this 
work. 
A dose rate distribution 7.34 mm from the inner surface of the plaque is presented in Figure 64.  
It is possible to see that it is radially isotropic and uniform. The effect of the six suture lugs on the 





Figure 63. Comparison of dose rate at the central axis of the plaque measured using film, 











































Figure 64. Dose rate distribution at the distance 7.34 mm from the inner surface of the plaque. 
View from the plaque. 0.5 cm between grid lines. 
 
4. Uncertainties. 
The complete analysis of uncertainties of 106Ru eye plaque dosimetry is part of the published 
article42. Analysis of 125I plaque dosimetry using radiochromic film is presented in Tables 8 and 9 
below. The main difference between 106Ru eye plaque dosimetry and 125I eye plaque dosimetry 
using radiochromic film is the radiation source used for film calibration. While film calibration 
using a Linac beam results in a combined uncertainty of 2.9%, the same calibration using a 
calibrated 125I seed results in a combined uncertainty of 6.6% due to high uncertainty in the air 
kerma strength of the calibration seed and in the TG-4353 parameters. This difference in film 
calibration uncertainty results in 14.6% combined expanded (k=2) uncertainty for 125I plaque 
dosimetry as compared to 8.6% combined expanded (k=2) uncertainty for 106Ru eye plaque 
dosimetry using radiochromic film. 
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Component of uncertainty Uncertainty % Type 
Uncertainty in a single film response from Table 242 2.3% A and B 
Uncertainty in calibration seed air kerma strength 
 
1.8% B 
Uncertainty in TG-4353 parameters of the calibration 
seed 
5.4% B 
Uncertainty in fitting parameters of the calibration 
curve 
1.5% B 
Combined standard uncertainty for film calibration 6.6%  
 
Table 8. Estimated uncertainties in film calibration using a 125I calibration seed. 
 
Component of uncertainty Uncertainty % Type 
Uncertainty in a single film response from Table 242 2.3% A and B 
Uncertainty in film calibration from Table 8 6.6% A and B 
Film non-uniformity 1.5% A 
Uncertainty in measurement depth 1.6% A and B 
Uncertainty in irradiation time 0.1% A 
Combined uncertainty 





Table 9. Estimated uncertainties in 125I eye plaque dosimetry using radiochromic film. 
 
5. Conclusions. 
Radiochromic film in a Solid Water phantom is a convenient, accurate, and reproducible 
dosimeter for 106Ru and low energy photon eye plaque dosimetry. The new special single layer 
films enable direct dose measurements on the inner surface of the plaques, providing precise 
assessment of the scleral dose, its uniformity, and of the active area of the plaques for coverage 
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determination. Cutting, preparation and handling of radiochromic films play an important role in 
precise absolute film dosimetry.  
The Scanditronix stereotactic diode is a precise reproducible dosimeter for eye plaque 
dosimetry, and can be used for either 106Ru or 125I absolute dosimetry. This thesis, for the first 
time, presents its use for absolute 125I dosimetry. 
 A calibrated 125I seed and the TG-4353 formalism can be used for calibrating radiochromic 
film and the Scanditronix stereotactic diode for absolute dosimetry. 
The ion-implantation technique developed by Implant Sciences Corporation can be used to 
manufacture dosimetrically reproducible 1 mm thick 125I eye plaques featuring uniform and 
symmetrical dose distributions without hot and cold spots. The dose rate of the Implant Sciences 
Corporation’s eye plaques is clinically relevant in accordance with the criteria of the American 
Brachytherapy Society96. The dosimetric results measured by film dosimetry and the 
semiconductor diode were in good agreement with each other and with Monte Carlo simulations 
of the same plaque. 
The collimator designed for the novel 125I eye plaque produces sufficiently uniform dose 
distributions in terms of hot and cold spots. The collimator concept should be further investigated 
since it is not clear if a reasonable number of collimated fields in combination with higher activity 
of the eye plaques can produce clinically viable dose rates. The effect of the divergence of the 
collimated beams on the possible treatment plan, however, is unclear. Lack of high resolution 3D 
imaging of ophthalmic tumors is an additional obstacle. 
This work validates the BrachyDose Monte Carlo simulations54 concerning the dose 
reduction effect by the plaque’s backing and the Silastic insert of COMS plaques. Clinical 
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implications of the dose rate reduction effect should be well understood prior to attempting to 
change well established treatment protocols. 
Monte Carlo simulations were successfully used for converting the dose rates measured 
using radiochromic film in Solid Water to those in liquid water. It was found that for the 
combination of film and Solid Water used in this work, the uncorrected method (all calibrations 
and measurements done in Solid Water using TG-4353 parameters for liquid water for calibration) 
produced very similar results to the same measurements corrected and converted using Monte 
Carlo simulations. The differences between the two methods are small when considering the 
uncertainties involved in the film dosimetry process, as well as in the Monte Carlo simulations. 
This conclusion has to be carefully checked for each combination of film and Solid Water, since 
the conversion factors can significantly differ between Solid Water 2.3 and Solid Water 1.7, as 
well as between different types of film. The data in this thesis indicates, when calculating the 
conversion factors between results in Solid and liquid water, it is insufficient to convert the dose 
between the different media, the film has to be modeled in Solid Water as well, since the difference 
in conversion factors with and without film was found to be as high as 16.8% for the particular 
combinations tested. 
The measured data provide a full 3D dosimetric characterization of the eye plaques, 
accounting for all heterogeneities used in their design, as well as dose non-uniformities, and can 
be directly used by applicable 2D or 3D treatment planning programs for treatment of patients, 
enabling delivery of correct doses and protection of critical structures.  
Each Ru-106 eye plaque must undergo accurate dosimetric commissioning and acceptance 
prior to its clinical use. Because of the history of conflicting dosimetric results, it is important to 
clarify the source of the dosimetry used in the prescription protocol. 
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Despite improved quality and dosimetry by BEBIG or recent advances in COMS plaques 
dosimetry, it is the ultimate responsibility of the medical physicist and physician to accept and 
commission the eye plaques for clinical use and decide what values to use for treatment delivery. 
6. Future directions. 
Production and standardization of the “eye” phantom and film punches would enable 
medical physicists to use these tools for commissioning and acceptance of eye plaques. Even if 
accredited dosimetry calibration laboratories will offer eye plaque calibration services, there will 
be institutions which will prefer doing their own acceptance and commissioning of eye plaques. 
Plastic scintillator systems for eye plaque dosimetry are not commercially available and not simple 
to build and calibrate.  
Regarding the novel 125I eye plaque project, the author discussed with its inventor Dr. 
Munro the possibility of re-activating the second prototype in a nuclear reactor and repeating its 
dosimetric measurements to test the hypothesis that these plaques can be re-activated and re-used. 
It would also be interesting to further test the collimator idea using the new thin unlaminated films. 
Recently, BEBIG created their own line of COMS plaques for customers outside of the 
U.S. Based on examination of two plaques of 16 mm and 20 mm diameters, these appear to be 
fabricated with a much higher quality than Trachsel’s plaques utilized in this work. BEBIG makes 
only the five classic COMS plaques with diameters 12 mm, 14 mm, 16 mm, 18 mm, and 20 mm 
per the exact geometrical COMS specifications. However, the gold alloy backing has a different 
material composition than Modulay, consisting of 86% gold, 11.5% platinum, and the remaining 
2.5% composed of zinc, iron, rhodium, and indium. The seed carrier insert is made from an 
unspecified biocompatible silicon. It is not clear if BEBIG’s COMS eye plaques result in the same 
 121 
 
dose reduction as Trachsel’s COMS plaques, given the different material compositions. Therefore, 
it would be important to test dosimetrically the BEBIG manufactured COMS plaques.  
If 3D imaging such as, high resolution CT, MRI and 3D ultrasound, becomes available for 
use in eye plaque treatments, treatment planning using dosimetric data acquired in the 
commissioning process of eye plaques may become a reality. 
7. Appendix 1. 
The accurate dosimetry methods, techniques and results as applied to 106Ru eye plaques are 
described in the published article42 below. The references in the article have double numbering; 
the numbers as they appear in the journal are shown in red, while the numbers shown in black are 
the running reference numbers of this dissertation. 
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Purpose: 106Ru eye plaques are widely used for treatment of intraocular malignancies, providing a 
good alternative to enucleation. Due to past dosimetric uncertainties, we routinely perform our 
own hospital-based acceptance testing and commissioning of 106Ru eye plaques using 
radiochromic film as recommended by ISO standard 21439:2009 “Clinical dosimetry-beta 
radiation sources for brachytherapy”. A Solid Water “eye” phantom with several novel features 
and related tools were developed for accurate radiochromic film dosimetry of eye plaques.  
Methods: The phantom enables full 3D dosimetric characterization of eye plaques. Films 
perpendicular to the central axis of the eye plaques are sandwiched between inserts in the phantom. 
Small holes in the phantom inserts enable marking the films with respect to the eye plaques, 
assuring exact geometrical co-registration. Special thin unlaminated radiochromic films were 
utilized, enabling dosimetric measurements virtually at the surface of the eye plaques. Precise film 
punches were developed in order to cut films with diameters as small as 8.5 mm and make cutouts 
in films without damaging the cut edges. The dosimetry method was validated using a silicon diode 
in a water tank and cross-calibrating one CCX type plaque with the U.S. National Institute of 
Standards and Technology (NIST). 
Results: Full dosimetric characterization of three CCX type and partial characterization of a CIA 
type 106Ru eye plaques is presented. Replicate film results were reproducible to within 4% - 5%. 
Even 4% non-uniformities in planar dose rates were easily detected. While the quality of post 2002 
plaques has substantially improved, the central axis dose rates were found 6% - 11.4% lower than 
the manufacturer’s data for two CCX plaques. The active area of one of the post 2002 plaques ends 
1.25 mm from the rim vs. expected 0.75 mm. Dosimetric hot spots were found near the rim of 
another of the post 2002 plaques. Comparison with recent Monte Carlo calculations of 106Ru 
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plaques by Hermida-López, Med. Phys. 40 (10), 2013 found good agreement along the central 
axis, but some lateral differences were found possibly due to construction variations of actual 
plaques. 
Conclusions: Accurate and precise 106Ru eye plaque dosimetry was achieved utilizing 
radiochromic film in the phantom introduced here. Co-registration of eye plaques and films 
permits not only precise treatment planning calculations along the central axis of the plaque, but 
also accounts for dosimetric non-uniformities using 2D or 3D methodologies. Dose measurements 
on the inner surface of the plaques provide precise assessment of the scleral dose, its homogeneity, 
and the active area of the plaques for coverage determination. With proper film calibration and 
irradiation geometry the technique can also be used for dosimetry of 125I eye plaques. 




Intraocular malignancies, although infrequent, are life threatening and may cause loss of 
vision. The two main kinds of primary intraocular tumors are choroidal melanomas and 
retinoblastomas, with approximately 2,500 new choroidal melanoma cases and 250 new 
retinoblastoma cases diagnosed annually in the U.S12. Historically the treatment consisted of 
enucleation of the eye, however with the advent by Stallard23 in 1961 of temporarily-applied 
episcleral eye plaques made of 60Co foil, radiation therapy for intraocular tumors has become a 
viable alternative to enucleation. Eye plaques provide good local control and survival rates similar 
or better than enucleation, and in many cases preserve vision3-66, 8, 9, 11. 
A range of mechanical designs and isotopes have been used for eye plaques since their 
invention, but currently the majority of eye plaques employ either 125I in the Collaborative Ocular 
Melanoma Study (COMS) design described by Chiu-Tsao7,831, 39 or beta emitting 106Ru eye plaques 
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introduced by Lommatzsch in 196497 and manufactured by Eckert & Ziegler BEBIG GmbH, 
Berlin, Germany. The COMS plaques are most commonly used in the U.S., while 106Ru eye 
plaques are the most popular in Europe. COMS plaques are assembled from 125I brachytherapy 
seeds, have localized hot spots and are 2.75 mm thick839, causing patient discomfort. 106Ru eye 
plaques are made of pure silver (Ag 99.99%) in the shape of a section of a hemisphere with an 
inner radius of 12 to 14 mm, which conforms to a typical human eye. They have a continuous layer 
of encapsulated radioactive material and are just 1 mm thick, offering greater patient comfort. A 
0.2 mm thick silver foil with a thin film of electrolytically deposited radioactive material is 
encapsulated between a 0.1 mm thick silver foil window and 0.7 mm thick silver backing, which 
absorbs approximately 95% of the beta radiation posterior to the plaque as reported by BEBIG and 
given in ISO International Standard 21439:20091041.  
As a beta emitter, 106Ru/106Rh provides better protection to critical parts of the eye due to 
a more rapid dose fall-off. On the other hand, this feature limits 106Ru eye plaques to treatment of 
tumors with apical heights no higher than 5 mm. The sharper dose gradients, however, require 
precise treatment planning based on accurate dosimetric information. Due to the design of 106Ru 
eye plaques they can be commissioned for use only by dosimetric measurements and are prone to 
dosimetric non-uniformities due to potential thickness variations of the radioactive layer and silver 
window. BEBIG, the manufacturer of the eye plaques, provides absolute central axis dose rate and 
relative surface dose rate normalized to the central axis measured using a plastic scintillator 
dosimetry system. Prior to May 1, 2002, BEBIG provided these measured dosimetric data for each 
eye plaque with a stated uncertainty of ±30% (k=2) using a scintillator with a diameter of 2.0 mm 
and height of 2.0 mm calibrated using ASMW standard of the former German Democratic 
Republic. Dosimetric results were delivered for only 4 points on the central axis and 9 surface dose 
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points on a circle for small plaques or 17 surface dose points on two concentric circles for the large 
plaques. Attempts by medical physicists to further reduce this uncertainty and to perform quality 
assurance measurements reported dose rate disagreements between -37% and +74% from the data 
supplied by the manufacturer for 8 out of 14 tested applicators1172 using a plastic scintillator system 
as well as up to -110% found in our measurements1275 using radiochromic film in a Solid Water 
phantom as reported in this work. Non-uniform dose distributions with off-axis hot and cold spots 
were reported using TLDs13, 1466, 68 and radiochromic film dosimetry in a Solid Water 
phantom12,1573, 75. A variety of methods were employed for 106Ru eye plaque dosimetry, including 
but not limited to TLDs13, 1466, 68, p-type silicon diode1667, extrapolation chamber15,1773, 160, plastic 
scintilators11,15,1869, 72, 73, radiochromic film dosimetry12,15,19,2071, 73, 75, 78, BANG gel21161 and liquid 
scintillator2078. Soares et al1573 did a cross comparison of eight measurement methods using planar 
and concave applicators. Due to the high dosimetric uncertainties 106Ru eye plaques prescription 
protocols did vary widely from institution to institution. This observation may explain why a 
comparison of various studies reported, that the “optimal apical and scleral doses have not yet been 
found”2287. 
Starting May of 2002 BEBIG introduced a small plastic scintillation detector with a 
diameter of 1.0 mm and height of 0.5 mm calibrated by the U.S. National Institute of Standards 
and Technology (NIST), which improved the uncertainty to ±20% (k=2)2381. BEBIG published 
conversion factors from the old ASMW dosimetry to the new NIST calibrated dosimetry2381 in 
form of ratios between the two techniques. For the smaller plaques like the CCX type presented in 
this work the ratios were as high as 2.06, since dosimetry of these small plaques has proved 
notoriously difficult. Dosimetric data was provided for 11 central axis points and 33 surface points. 
At the same time BEBIG introduced improved manufacturing processes, but a recent 
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publication24162 however still reported source non-uniformities of 13 – 20%. Following the 2002 
NIST calibration 106Ru eye plaque dosimetry was extensively reviewed by ICRU 7225121, 
Netherlands Report on Beta Dosimetry26163 and ISO Standard 21439:20091041. The latter standard 
while not excluding other methods, selected as recommended methods for beta dosimetry 
radiochromic film, plastic scintillators, silicon diodes and TLDs. Measurements by Kaulich et 
al2774 using plastic scintillators, Heilemann et al24162, as well as our measurements presented in 
this work using radiochromic film demonstrated substantial improvement by the manufacturer of 
the eye plaques post 2002 NIST calibration. While improved plastic scintillation systems28, 29164, 
165 enable fast and precise eye plaque dosimetry, they are not available commercially and not easy 
to build and make more sense for institutions using large numbers of 106Ru eye plaques. The silicon 
diode1667 remains a good reliable method for central axis dosimetry and can be used for validation 
of other methods12,2475, 162, however radiochromic film still is a good choice for multidimensional 
eye plaque dosimetry for institutions using limited numbers of 106Ru eye plaques. Development of 
new films, like EBT3 used by Heilemann et al24162 and special thin EBT1 and unlaminated EBT3 
presented in this work enable full dosimetric characterization of eye plaques in a matter of days as 
opposed to weeks using older HD-810 and MD-55-2 film models. 
In addition to the absolute dose calibration and dose uniformity, there is a question of 
dosimetric coverage close to the rim of the plaque. In the past BEBIG has shown in the applicator 
drawings that the radiation coverage ends 0.6 – 0.75mm from the rim of the plaque for most eye 
plaques. The most recent manufacturer’s User Manual3030 states an inactive border of 0.75 mm for 
most eye plaques, and there are also several types not discussed here with larger inactive areas; 
thus this inactive border has to be verified by measurement as part of the commissioning process.  
Taccini et al1971 found that in the region 1 mm from the rim of the plaque, the dose decreases to 
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less than 40% of the uniform value. Barker et al3188 report a higher than anticipated number of 
local tumor recurrences when using 106Ru eye plaques and suggest adding a 3 mm margin to the 
tumor size when selecting the plaque, which may indicate insufficient coverage close to the rim of 
the plaque. 
The recently published Guidelines by AAPM and GEC-ESTRO on the use of innovative 
brachytherapy devices and applications3289 state that 106Ru eye plaques have to be dosimetrically 
calibrated by the clinical medical physicist prior to clinical use. There are currently no primary 
calibration standards in the U.S. for these plaques, and thus, there is no ADCL calibration 
available. Therefore, 106Ru eye plaques need to be individually commissioned dosimetrically. 
This work focuses on a radiochromic film dosimetry technique, which we developed in 
2001 prior to NIST calibration of 106Ru eye plaque dosimetry1275, in order to provide accurate 
dosimetric information for treatment of patients. The technique was continuously developed, 
refined and used by us over the last fifteen years not only for 106Ru eye plaques, but also for 125I 
plaques dosimetry, including a large 20 mm COMS plaque; the 125I plaques dosimetry will not be 
discussed in this work in the interest of brevity. A small silicon diode in a water tank similar to the 
one used by Lax1667 was used in the initial stages of this project for comparison with the film 
results as a secondary check. In addition, a cross-calibration comparison of the same 106Ru eye 
plaque between our measurements and NIST was performed and found in good agreement. The 
results of the comparison were used by Kirov et al2078 for validation of the liquid scintillation 
dosimetry technique. 
Since the use of 106Ru eye plaques is very limited in the U.S. and between 2007 and 2011 
the manufacturer did not deliver these plaques to the U.S., full dosimetric characterization was 
done only for eight eye plaques, six of which belong to the CCX type, which was of special interest 
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at our institutions for treatment of retinoblastoma in small children. The results of dosimetric 
measurements of three CCX type 106Ru eye plaques are reported here to demonstrate the technique 
and to publish experimental data on this type of eye plaques, since Hermida-López3379 attempting 
to compare Monte Carlo simulations to experimental results could find in the literature only our 
own very old results of a CCX eye plaque2078. In addition brief results of a CIA type plaque are 
presented in order to demonstrate dosimetric data of a plaque with a cutout and point out a potential 
treatment problem. 
2. Materials and methods 
 
2.1. Solid Water “eye” phantom 
 
A Solid Water “eye” phantom was constructed from Gammex 457 Solid Water™ (Gammex, 
Middleton, WI, Sun Nuclear Corporation) water-equivalent plastic. Solid Water, a composition 
developed by Constantinou34166 as an optimal material for calibrations of photon and electron 
beams is the most frequently used water equivalent solid material for in-phantom brachytherapy 
dosimetric measurements25121. Its density of ~1.04 g/cm3 is very close to that of water, so it has 
been suggested to be used for beta dosimetry10,2541, 121. Solid Water is delivered as slabs and may 
have non-uniformities within the slabs, which can be detected with radiography. The slab used to 
manufacture the “eye” phantom developed in this work was radiographed prior to creating the 
phantom and was found to be uniform. The central part of the phantom mimics the main 
dimensions of a human eye, which has a surface curvature with a radius of approximately 12 mm. 
The typical eye dimensions are 24.2 mm transverse horizontal x 23.7 mm sagittal vertical x 22.0 
– 24.8 mm axial anteroposterior3565. The cross section of the phantom with a CCX 106Ru eye plaque 
is shown in Figure 1. The phantom consists of a 20 mm high cylindrical body and a 10 mm high 
cylindrical cap with an outer diameter of 50 mm. The inside diameter of the cylindrical body is 30 
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mm, enabling the use of films with a maximum diameter of 30 mm. This dimension is sufficient 
for measuring the dose to any part of the eye and its close surroundings. The cylinder is filled by 
Solid Water cylindrical inserts with thicknesses of about 1 mm, 2 mm, and 5 mm. The film is 
sandwiched between the inserts perpendicular to the central axis of the plaque. Various 
combinations of inserts enable positioning of films from ~1 mm to almost 19 mm from the inner 
concave surface of the plaque. The space between the concave surface of the plaque and the top 
cylindrical insert is filled with parts shaped as segments of a hemisphere, which enable placement 
of smaller diameter films perpendicular to the central axis of the plaque as close as 1 mm from the 
plaque’s surface along the central axis. Sufficiently thin and flexible films can be made to conform 
to the curved surface of the plaque, enabling measurements a few µm from the inner surface of the 
plaque, limited only by the thickness of the active layer of the film. 
Several parts of the phantom, which are in direct contact with the eye plaque, are manufactured 
in a way which assures a tight fit without air gaps. Each type of eye plaque needs this tight fit in 
order to achieve precise and reproducible positioning of the eye plaque with respect to the phantom 
and to the film. The cylindrical cap, which is the upper part of the phantom, has an inside opening 
in the shape of the outside of the plaque (imprint of the plaque) and is designed to hold the plaque 
tightly in place. Thus the plaque position is fixed with respect to the films for the duration of the 
measurements. 
The design of the phantom enables co-registration between the plaque and the films which 
allows not only measuring 2D dose distributions in the plane of the film, but reconstruction of 3D 
dose distributions from a set of films irradiated in planes perpendicular to the central axis of the 
plaque. This configuration enables accounting for dosimetric source non-uniformities during 
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treatment planning. In order to better understand the co-registration feature, the top view of a 
cylindrical insert with a CCX 106Ru eye plaque placed within the phantom is shown in Figure 2. 
             
 
Figure 1. Cross section of the Solid Water “eye” phantom shown with a CCX 106Ru eye plaque 
(all dimensions in mm). 
 
The cylinder housing the inserts and films has two key structures (Solid Water pins) to hold 
the inserts in fixed positions, while the inserts and films have appropriate cutouts. This design 
assures that the disks and films are always placed in the same position, i.e. effectively eliminating 
the rotational degree of freedom of the disks and films, which is important for co-registration 
between the plaque and films. 
Each insert has four holes located on its periphery, as can be seen in Figure 2. The holes 
have 1 mm diameters, are located in fixed positions with respect to the eye plaque, and are 
coincident for all inserts. A thin needle inserted through the holes is used to make marks on the 
film. Three holes are used to co-register the film and plaque. During film analysis these three marks 
enable creation of two perpendicular lines in the film plane (coordinate axes X and Y) which pass 
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through the film center. The intersection of axes X and Y coincides with the central axis Z of the 
plaque. The fourth hole is necessary in order to know which side of the film faced the plaque. The 
cylindrical inserts which are close to the eye plaque have holes or openings to accommodate the 
suture lugs of the plaques. 
   
Figure 2. Top view of an insert of the “eye” phantom with a CCX 106Ru eye plaque, inserted into 
the phantom, showing the key structures (Solid Water pins), and holes for marking the films (all 
dimensions in mm). The key structures are solid black for visibility. A – A marks the cross-section 
shown in Figure 1. 
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The disassembled Solid Water “eye” phantom and some of its various inserts are shown in 
Figure 3 along with a CCX 106Ru eye plaque and an exposed unlaminated EBT3 film. The key 
structures can be seen inside the phantom’s body, while the openings for the key structures as well 




Figure 3. Solid Water “eye” phantom with its various inserts, a CCX 106Ru eye plaque and an 







While the design of the phantom enables performing measurements on any type of an eye 
plaque, measurements of photon sources like 125I require placement of the loaded phantom into an 
appropriate scatter phantom, since the photon scatter contribution to the absorbed dose for 125I can 
be as high as 38%36106. For 106Ru eye plaque measurements the assembled phantom with the film 
and eye plaque was first inserted into a 5 cm diameter cylindrical hole at the center of a 30 cm x 
30 cm x 3 cm Solid Water slab which was on top of a 5 cm thick Solid Water slab and covered by 
another 5 cm thick Solid Water slab. The main goal of this measurement setup was to assure that 
the phantom with the eye plaque and film were kept together for the duration of the measurement, 
as well as creating consistent scatter conditions, even though the phantom alone provided sufficient 
scatter conditions, as was tested with and without the additional scatter phantom. 
2.2. 106Ru eye plaques 
 
 The phantom was used to dosimetrically characterize 106Ru eye plaques belonging to CCX, CCA 
and CIA types. The CCX has a diameter of 11.6 mm and internal height of 1.3 mm and belongs in 
terms of its dimensions to the smallest plaque types manufactured by BEBIG. It is of special 
interest for treatment of retinoblastoma in small children. The CCA has a diameter of 15.3 mm 
and internal height of 2.3 mm, while the CIA designed for treatment of ciliary body melanomas3030 
has the same dimensions as the CCA, but has a cutout in order to avoid radiation to the iris. Results 
of CCX 55, CCX 129, CCX 219, and partial results of CIA 156 plaques are reported in this work. 
The three digit number after the plaque type is its serial number. 
106Ru /106Rh emits beta-radiation with a maximum energy of 3.541 MeV, as well as 20% 0.512 
MeV, 10% 0.622 MeV, 1.6% 1.05 MeV, 0.4% 1.13 MeV, and 0.2% 1.55 MeV gamma radiation 
per decay1041. Bremsstrahlung is also present. The main contribution to the therapeutic dose comes 
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from the beta radiation3762. The half-life of the parent isotope is 373.59 days1041. Each 106Ru eye 
plaque measured in this work has two suture lugs used to attach it to the sclera. 
2.3. Radiochromic film 
 
All radiochromic films used in this work were GAFCHROMIC™ films manufactured and 
provided by International Specialty Products (Wayne, NJ), now Ashland (Covington, KY). The 
thickness and construction of the film are very important for eye plaque dosimetry and particularly 
dosimetry of beta emitting 106Ru eye plaques with dose gradients of ~30%/mm, especially in the 
proximity of the concave surface of the plaque. The dosimetric measurements of the CCX 55 eye 
plaque were done using MD-55-2 film Lot #I1215. This was a film consisting of two active layers 
separated and covered by adhesive and transparent polyester layers for a total of seven layers as 
described by Soares et al38113.  A 30 Gy dose to the film was required in order to achieve an optical 
density of at least 0.5, which resulted in irradiation times between a day and a week per film, 
depending on the film distance from the plaque’s surface. The dosimetric measurements of the 
CIA 156 plaque were done using EBT film Lot # 34141 2x2IL. The construction of EBT film is 
shown in Figure 4-a. This was still a relatively thick film consisting of five layers, but required 
only 200 cGy for optical density of about 0.5. The construction of the EBT film enabled the closest 
measurement at 117 µm from the eye plaque surface, which is the middle point of the film, but 
this thickness and design make the film rather rigid and hard to bend to the radius of curvature 
necessary to measure the dose close to the surface of an eye plaque. Importantly, no other 
dosimeter, including TLD’s, plastic scintillators, or semiconductor diodes, can measure the dose 
closer than about 0.5 mm - 1.0 mm from the surface of the plaque due to geometrical and 
mechanical limitations, forcing one to rely on extrapolated values for determination of the scleral 
dose. For 106Ru eye plaques the central axis surface dose was reported by the manufacturer in the 
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plaque certificates until 2014 extrapolated from plastic scintillator measurements the closest of 
which was 0.6 mm from the surface. Currently, the manufacturer measures the dose rate as close 
as 0.48 mm from the surface and has eliminated the extrapolated surface dose from the plaque 
certificates, but provides it to customers upon request (private communication with BEBIG). For 
these reasons, International Specialty Products created for this work special thin radiochromic 
film, referred to here as EBT1 and shown schematically in Figure 4-b. It consists of half of the 
regular EBT film shown schematically in Figure 4-a. In this film the active layer is covered just 
by 3 µm of protective coating on one side. This film, due to the lack of the thick polyester layer is 
very flexible and therefore permits direct contact of the active layer of the film with the eye plaque 
surface for surface dose measurements. This EBT1 film Lot# 35314-4H was used for dosimetric 
characterization of the CCX 129 106Ru eye plaque. 
 





Figure 4. a - structure of EBT film, b - structure of special thin EBT1 film, c - structure of 
unlaminated EBT3 film. 
 
a b 
surface layer - 3 microns
active layer - 17 microns
clear polyester - 97 microns
c 
    active layer - 14 microns
  clear polyester - 125 microns
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The CCX 219 eye plaque was characterized using the new commercially available unlaminated 
EBT3 film Lot#02171601, which consists of a 125 µm thick clear polyester substrate and a 14 µm 
thick active layer without any protective coating as shown in Figure 4-c. 
These thin films enable dosimetric measurements virtually at the surface of the eye plaques 
providing the doses to the outer sclera, which are an important factor in prescribing the treatment, 
since the sclera is considered a critical organ when prescribing to the apex of the tumor or is used 
by some institutions which want to deliver a minimum dose to the tumor base as the prescription 
point. In addition, measurements on the plaques surface also provide information on the radiation 
field fall-off at the rim of the plaque for proper plaque selection. The surface dose measurements 
also provide a good idea of the source non-uniformity, which causes dosimetrically hot and cold 
spots on the sclera and affect the doses delivered to the tumors and critical structures of the eye, 
but in this work we did not attempt covering the whole internal concave surface of the eye plaque 
with film, instead using planar films perpendicular to the plaques’ central axis for determination 
of source non-uniformity, as permissible in accordance with ISO Standard 21439:20091041.   
2.4. Preparation and handling of the appropriate sizes and shapes of films 
 
Eye plaque dosimetry using our “eye” phantom required precise cutting of round films with 
diameters as small as 8.5 mm or thin strips, which could be placed on the plaques’ concave surface, 
without separation of layers of the film and without rough edges, which could create air gaps 
between the films and the inserts of the phantom. A set of unique punches based on precise 
instrument dies custom made by Dayton Lamina Corporation (Dayton, OH) shown in Figure 5 
was created by the instrument shop of Memorial Sloan-Kettering Cancer Center for this purpose. 
The punches enabled us to cut films of any size and shape even with the special cutouts to 
accommodate the key structures of the “eye” phantom without damaging parts of the film and 
 137 
 
leaving clean flat edges. The direction of the coating was marked on each film prior to cutting, 




Figure 5. Special film punches. 
 
GAFCHROMIC™ films have a certain degree of moisture content which necessitates 
equilibration to the environment38113. From our experience, if the films are cut immediately prior 
to measurements, the moisture content can change the readout optical density by as much as 10% 
and result in non-uniform areas on the film. Thus, films used for calibration and eye plaque 
measurements were pre-cut at least several days prior to measurements to enable the films to 
equilibrate with the environment. Each cut film was kept in a separate light-tight paper envelope 
until irradiation and subsequent scanning. 
2.5. Film calibration and scanning 
 
For calibration of MD-55-2 film used for dosimetry of the CCX 55 plaque, 17 2 cm x 2 cm films 
with marked direction of coating were irradiated to doses between 20 cGy – 5000 cGy using a 
60Co machine as recommended by TG-553998 for electron dosimetry. The TG-553998 
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recommendation is based on comparison of film calibrations using well- characterized 60Co 
gamma-ray beams and 90Y beta particles. The agreement between both calibrations can be 
explained since the dose in 60Co beams in condensed media is being mainly imparted by secondary 
electrons with an energy spectrum similar to the beta particles of both 90Sr/90Y and 106Ru/106Rh. 
Any differences would be negligible. Moreover, as was shown by Monte Carlo calculations40103, 
the restricted mass collision stopping power ratios and ratios of mass-energy absorption 
coefficients for the sensitive materials in radiochromic films relative to water are almost constant 
in the energy range of interest in this work between 100 KeV and 6 MeV. Therefore the film 
response to 106Ru eye plaques as well as to calibration energies used in this work can be assumed 
energy independent. The films were irradiated in a 30 cm x 30 cm Solid Water phantom at 0.5 cm 
depth (Dmax) with 10 cm backscatter. For calibration of EBT, EBT1 and unlaminated EBT3 films, 
a page of film was cut using a precise office paper cutter into 2 cm x 2 cm pieces, while marking 
at the upper left corner of each piece the coordinate of the piece on the page in form of the row#-
column#. The location of the mark in the upper left corner fixed the coating direction of the film, 
which is important in the subsequent scanning process. For irradiation the pieces of film were 
randomized to dose levels using the random number generator of Microsoft Excel, thus 
randomizing possible non-uniformities in the page of film. For calibration of EBT film used for 
dosimetry of the CIA 156 plaque 22 films were irradiated to doses between 20 cGy and 440 cGy 
using a 60Co machine. The films were irradiated at the same setup as the MD-55-2 film in a 30 cm 
x 30 cm Solid Water phantom at 0.5 cm depth (Dmax) with 10 cm backscatter. Since the 60Co 
machine is not available anymore, both the EBT1 and unlaminated EBT3 films were calibrated 
using a 6 MeV linac electron beam calibrated in terms of dose to water using TG-5141145 protocol 
at the depth of 1.4 cm (Dmax) with 10 cm backscatter in a 30 cm x 30 cm Solid Water phantom 
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similar to the beam used by Lax1667 for calibration of the silicon diode. To calibrate the EBT1 film 
batch, 19 films were irradiated in 40 cGy increments up to 600 cGy and in 100 Gy increments 
between 600 cGy – 1000 cGy. To calibrate the unlaminated EBT3 film batch 21 films were 
irradiated to doses 30 cGy – 600 cGy in 30 cGy increments. 
All irradiated films along with unexposed films defining the background pixel value were scanned 
either 24 or 48 hours after the end of irradiation in order to let the polymerization process stabilize 
and have all films scanned at the same level of post-exposure growth3998. The MD-55-2 Lot #I1215 
films were scanned 48 hours after irradiation using an AGFA ARCUS II flatbed scanner (Agfa-
Gevaert N. V., Mortsel, Belgium) with a red acetate filter42120 and RIT113 Film Dosimetry 
software (Radiological Imaging Technology, Inc., Colorado Springs, CO). The EBT films Lot # 
34141 2x2IL used for dosimetry of CIA 156 plaque were scanned 24 hours after exposure using a 
Vidar VXR 16 Dosimetry Pro 16 bit film scanner (Vidar Systems Corporation, Herndon, VA) at 
89 micron resolution and RIT113 Film Dosimetry software with films placed into clear plastic 
sheet protectors together with a yellow acetate filter. The red channel provides optimal response 
for GAFCHROMIC film38113, but since the RIT software was limited to monochrome (16 bit) 
scanning, we had to use the red acetate filter for MD-55-2 film42120 and the yellow acetate filter 
for EBT film (as recommended by the company), in order to maximize film response. The EBT1 
films Lot# 35314-4H and the unlaminated EBT3 films Lot# 02171601 were scanned 24 hours after 
exposure using an Epson Expression 1680 flatbed scanner (Seiko Epson Corporation, Nagano, 
Japan) and EPSON Scan software in 48 bit RGB mode with all filters and image enhancements 
de-activated, followed by extraction of the red channel. The films were scanned one at a time at 
resolution of 254 dpi (100 microns pixel size) and saved as TIFF files. 
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Both calibration and eye plaque films were always placed at the center of the scanner bed. The 
EBT1 films were lightly attached to the scanner bed using adhesive tape at the edges of the film 
to avoid Newton ring artifacts. The unlaminated EBT3 films were always flat on the scanner and 
did not require attachment. Films were scanned in the same portrait orientation with respect to the 
original sheet of film marked on each film. All CCD scanners suffer from the lateral response 
artifact43,44123, 124 resulting in decreased pixel values (increased measured optical density) toward 
the lateral edges of the scanner bed, but since the films used in this work were small and always 
positioned at the same location at the center of the scanner, reader bed positioning corrections were 
not required38113. 
Following scanning, and extraction of the red channel when required, the average pixel value of a 
1 cm x 1 cm region of interest was measured using the film dosimetry software. Then the 
calibration curves in the form of pixel values vs. dose were fitted with analytical functions 
suggested by the curve fitting program CurveExpert Professional software by Daniel G. Hyams, 
Madison, AL.  
2.6. Eye plaque film dosimetry and data analysis 
 
Eye plaque films were irradiated one depth at a time, so that approximately the same dose is 
delivered to each film, usually around 30 Gy for MD-55-2 film, 200 cGy for EBT film, 200 – 400 
cGy for EBT1 and unlaminated EBT3 films, which would produce optical density around 0.5 in 
the high dose area of the film. All eye plaque films were scanned at the same post exposure time 
as the calibration films, i.e. 48 hours for the CCX 55 plaque, and 24 hours for all other plaques.  
Applying the calibration curve and conversion of the pixel values of the scanned films to dose, as 
well as the film analysis was done using Memorial Sloan-Kettering Cancer Center’s Contour film 
dosimetry software package, which was customized in order to accommodate requirements of this 
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work. Since each film was irradiated at different dates and times, the 2D dose distributions were 
converted to dose rate distributions at a certain reference date and time, using the film irradiation 
dates and times, and 106Ru decay constants. 
The calibration films were exposed in Solid Water to a 60Co beam or 6 MeV electrons calibrated 
to absorbed dose values to liquid water. The eye plaque films were irradiated in Solid Water; 
therefore, it is possible to assume that the measured doses are close to doses in liquid water, 
assuming that both phantoms, the calibration phantom and the “eye” phantom are made from the 
same kind of Solid Water. While we did not find publications testing the dependence on kind of 
Solid Water for 60Co, linac and 106Ru energies, Meigooni et al45135 found that certain batches of 
Solid Water may have 1.7% calcium content, while other batches may have 2.3% calcium content, 
and depending on calcium content in Solid Water, Monte Carlo calculated dose conversion factors 
from Solid Water to liquid water may vary by as much as 5% for 125I. Therefore, exact knowledge 
of calcium content of the Solid Water is very important. For example, Patel et al.46138 performed 
chemical analysis of Solid Water, finding 1.6% calcium content, in contrast to the manufacturer’s 
stated value of 2.3%. The manufacturer’s reported calcium content of the non-certified Solid Water 
slab used to manufacture our phantom was 2.31%. To verify this, one of the inserts of our phantom 
was sent for chemical analysis to the same laboratory used by Patel et al46138 (Analytical Answers, 
Inc., Woburn, MA). Resultant gravimetric ashing and scanning electron microscopy/energy 
dispersive X-ray spectroscopy revealed calcium content of 2.32 ± 0.06% consistent with the 
manufacturer’s report. Our calibration phantom consists of certified Solid Water with 2.3% 





2.7. Silicon diode dosimetry 
 
In addition to the primary dosimeter it is important to have a secondary dosimetric system for 
independent verification of the measurements by the primary system. Lax1667 successfully used a 
p-type Scanditronix silicon diode for absolute 106Ru eye plaque dosimetry. A p-type silicon diode, 
the Scanditronix Stereotactic Field Detector (SFD) model DEB050 (Scanditronix Medical AB, 
Uppsala, Sweden, currently IBA Dosimetry GmbH, Schwarzenbruck, Germany) in a Scanditronix 
RFA200 water tank was used for 106Ru eye plaque dosimetry for both, treatment planning of 
patients and validation of the radiochromic film dosimetry technique. 
This diode detector has a 60 µm typical effective thickness of the measurement volume with a 0.6 
mm ± 0.1 mm detector diameter, and a distance of 0.61 mm ± 0.15 mm displacement of the 
effective measurement point from the front surface of the detector. Externally, the detector is a 4.0 
mm diameter cylinder which was oriented along the central axis of the eye plaque. The closest 
measurement point of the diode was 0.87 mm from the inner surface of the plaques due to the 
concave shape of the plaques and the 4.0 mm diameter of the diode both of which limited how 
close the diode can come to the surface of the plaque. The eye plaque was attached using Dow 
Corning High Vacuum grease (Dow Corning Corporation, Midland, MI) to the cap of the Solid 
Water “eye” phantom placed upside down, and the cap was attached using the same grease to a 
Lucite base positioned at the bottom of the water tank. The cap was used for this purpose since it 
had a customized imprint of the particular eye plaque. A special Lucite centering jig was created 
to assure that the diode was precisely centered on the central axis of the eye plaque and was not 
displaced laterally from the axis. The arrangement is shown in Figure 6. After setup the Lucite jig 
was removed for measurements. 
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For 106Ru eye plaque dosimetry, the diode was calibrated in a 6 MV linac photon beam in the water 
tank. This diode dosimetric system was used for the initial 106Ru eye plaque dosimetry cases, until 




Figure 6. Lucite centering jig for the stereotactic field detector measurement setup shown with a 




Dosimetric measurements of CCX plaques S/N 55, 129 and 219, as well as partial results 
of CIA plaque S/N 156 are reported here. 
Dosimetry of the CCX 55 plaque was done using MD-55 film in our Solid Water “eye” 
phantom, as well as with the Scanditronix Stereotactic diode in the Scanditronix RFA200 water 
tank. Seven films were irradiated between 1.835 mm to 7.445 mm from the inner surface of the 
plaque (measured from middle of the film). The use of three digits after the decimal point to define 
the distance from the plaques does not result from depth measurement with 1µm precision, but 
from adding the thickness of the phantom parts measured with a micrometer and the distance to 
the middle of the active layer of the film or to the middle of the film if two active layers are present, 
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calculated from the film specifications provided by the manufacturer. Three films were irradiated 
at 3.445 mm from the inner surface of the plaque to test reproducibility. The measured central axis 
dose rates of the three films agreed to within ± 5%. Diode measurements were done on the central 
axis every 0.5 mm between 0.87 mm and 10.87 mm from the inner surface of the plaque. Depth 
dose curves measured on the central axis of the plaque using either film or the diode, as well as 
the central axis depth dose curve provided by BEBIG, are shown in Figure 7. Both techniques – 
the silicon diode and the radiochromic film dosimetry are in close agreement. The ratio of the dose 
rate measured using the diode to the dose rate measured using film is 1.06, which is well within 
the uncertainties (k=2) of our measurements as reported below. The curves demonstrate a major 
discrepancy between our measurements and manufacturer’s data. This plaque was manufactured 
prior to the 2002 calibration of 106Ru eye plaques at the U.S. National Institute of Standards and 
Technology (NIST), which became the calibration standard for BEBIG. The ratios of the dose 
rates on the central axis of the CCX 55 plaque measured in this work and the same ratios measured 
at NIST for another CCX type eye plaque are shown in Table 1. The ratios measured in this work 
agree to within 5.5% at the closest point to the plaque and show much better agreement with the 
NIST measurements further from the plaque. This is considered very good agreement in beta 
dosimetry, where even for relative dosimetry not accounting for the calibration uncertainty of 







Figure 7. Dose rate along the central axis of the CCX 55 eye plaque. 
 
Distance from plaque 2.0 mm 3.5 mm 5.0 mm 
Ratio of our measurements to BEBIG’s data 1.55 1.81 2.11 
Ratio of NIST’s measurements to BEBIG’s data 1.64 1.83 2.06 
Agreement of our measured ratios with NIST -5.5% -1.1% 2.4% 
 
Table 1. Ratios of measurements on the central axis of the plaque to the data provided by BEBIG. 
 
Isodose distributions measured using films at three different depths from the plaque are shown in 
Figures 8-a, 8-b and 8-c. Each of the films has a hot spot at the same location. The intensity of the 
hot spot vs. the central axis (CAX) value is ~28% for the 1.835 mm film, ~14% for the 2.465 mm 








































Figure 8. Dose rate in three planes perpendicular to the central axis of the CCX 55 plaque at depths 
a - 1.835 mm 28% hot spot, b - 2.465 mm 14% hot spot, and c - 3.445 mm 4% hot spot. View 
from the plaque. 0.5 cm between grid lines. 
 
Dosimetric characterization up to relevant clinical depth of the CCX 129 plaque was done 
placing films at nine distances between 0.012 mm and 7.632 mm from the inner concave surface 
of the plaque. Several films at various distances were repeated in order to test reproducibility. 
Results on duplicate films agree within 4%. Dosimetric characterization of CCX 219 plaque was 
done placing films at eight distances between 0.007 mm and 6.637 mm from the inner concave 
surface of the plaque. Several films at various distances were repeated to test reproducibility with 
agreement between duplicate films within 3%.  
Figures 9-a and 9-b display measured dose rate distributions of both plaques and Figures 10-a and 
10-b display our measured dose rate on the central axis of both plaques as compared to the data 
provided by the manufacturer along with fitted curves. 











Figure 9. Measured dose rate distribution at a - distance 2.642 mm from the inner surface of the 
CCX 129 eye plaque and b - at distance 2.637 mm from the inner surface of the CCX 219 eye 





Figure 10. Measured dose rate along the central axis of a - the CCX 129 plaque and b – the CCX 








































































Both dose distributions look uniform and symmetric, without visible hot and cold spots, while the 
CCX 219 plaque shows wider coverage, which possibly results from manufacturing variations. Its 
diameter was found to be 11.70 mm as measured by digital Mitutoyo (Mitutoyo America, Aurora, 
IL) calipers vs. 11.45 mm for the CCX 129 plaque. 
The measured central axis depth dose rate of the CCX 129 plaque is on the average 6% lower than 
the manufacturer’s provided data in the first 5.62 mm from the plaque, while the dose rate of the 
CCX 219 plaque is on the average 11.4% lower at the same 5.62 mm distance. Further away from 
the plaque the measured dose rate becomes about 1% higher than the manufacturer’s.  Both results 
are well within the ±20% (k=2) dosimetric uncertainty stated by the manufacturer, which reflects 
among others a ±15% (k=2) uncertainty on the NIST calibrations of manufacturer’s equipment, as 
stated in the User Manual of the eye plaques3030. These plaques were manufactured ten years apart 
and during this period the manufacturer’s dosimetry system had an additional periodic re-
calibration by NIST, as well as replacement of the calibrated plastic scintillator tip. Both could 
contribute to the dosimetric difference between the plaques, which is accounted for in the stated 
±20% (k=2) dosimetric uncertainty. 
In order to measure the dose rate near the surface of the plaques, 3 mm wide strips of film were 
attached to a hemispherical part with the inner diameter of the plaque in either of two perpendicular 
directions – a radial, where the film was in the middle between the suture lugs or the transverse 
direction. In both cases the central axis of the plaque passed through the center of the 3 mm film 
strip. The distance of the measurements from the inner surface of the plaque was taken as the 
middle of the active layer, as in all other measurements. The EBT1 measurements were 0.012 mm 
from the inner surface, and the unlaminated EBT3 measurements were 0.007 mm from the inner 
surface. In addition to directly measuring the surface dose, these measurements enable assessment 
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of the uniformity of the radioactive layer just under the surface of the plaque, providing a measure 
of the dose uniformity on the inner sclera and of the coverage in the vicinity of the rim. Obviously, 
this is just a sample of the total inner surface of the plaques. Profiles through two radial films are 
shown in Figure 11. 
As it can be seen from the profiles in Figure 11, the CCX 219 plaque has wider coverage, actually 
as already mentioned, and its diameter is 0.25 mm larger than the diameter of the CCX 129 plaque. 
The CCX 219 plaque also has pronounced hot spots at the edges of the radiation field, which are 




Figure 11. Profiles in the long direction through radially placed on the inner surface of the eye 




































In order to assess the coverage of the plaques, the length of a circular sector on the inner surface 
of the plaque passing through the central axis of the plaque was calculated from simple geometry, 
knowing 12 mm, which is the inner radius of the plaque and 1.3 mm is its the internal height. This 
length is 11.2 mm. From the profiles in Figure 11, the “flat” area before the dose fall-off starts for 
the CCX 129 plaque is between -4.5 mm and 4.2 mm, for a total covered area of 8.7 mm, and for 
the CCX 219 plaque it is between -5.0 mm and 4.8 mm, for a total of 9.8 mm. These are lengths 
of full radiation coverage, excluding the penumbra. This coverage limitation should be well 
understood when selecting a plaque for treatment and is another reason to commission the plaques 
prior to clinical use, since otherwise the tumors will not be fully treated as suggested by Barker et 
al3188 based on tumor recurrences.  
Comparison of our measurements with the Monte Carlo simulations done by Hermida-López3379 
is shown in Figures 12 and 13. In Figure 12 the Monte Carlo calculated dose rate along the central 
axis of a CCX plaque is compared with the analytically fitted measurements of the CCX 129 and 
CCX 219 plaques. The three curves are normalized at the depth of 1 mm as done by Hermida-
López3379. The CCX 129 measured point by point ratio to the Monte Carlo results is on the average 
1.00, while the same ratio for the CCX 219 plaque is 1.03. It can be noticed that at the inner surface 
(0.0 mm depth) the Monte Carlo overestimates the measurement by 5%, while at the next point 
(0.5 mm depth) the Monte Carlo overestimates the measurement by 2% for both plaques.  
In Figure 13 the relative lateral dose rate profiles of CCX plaques calculated by Hermida-López3379 





Figure 12. Relative dose rate along the central axis of CCX plaques calculated by Hermida-
López3379 compared with analytically fitted measured results of the CCX 129 and CCX 219 
plaques. All curves are normalized at 1 mm depth. 
 
 
Figure 13. Relative lateral dose rate profiles of CCX plaques calculated by Hermida-López3379 
compared with measured results of the CCX 129 and CCX 219 plaques. All curves are normalized 









































































For this comparison, the experimental 2D dose rate distributions were smoothed using median 9 x 
9 filtration prior to deriving the lateral profiles. The median filter replaces the value of each pixel 
with the median value of a group of pixels surrounding the particular pixel. The resultant profiles 
were made symmetrical by averaging between the left and right sides of the profile. The Monte 
Carlo calculations depths coincide with the experimental results only at depth of 2.0 mm. 
Therefore the lateral Monte Carlo results were interpolated using analytical fits between 2.0 mm 
and 3.0 mm depth and between 3.0 mm and 4.0 mm depth to enable comparison with the film 
measurements at depths of 2.64 mm and 3.63 mm. It can be seen from Figure 13 that the Monte 
Carlo calculations underestimate the width of the lateral profile. It is possible that the differences 
between the calculated and measured data are due to differences between the ideal plaque used for 
modelling and the actual plaques. Even the two plaques characterized in this work have a 0.25 mm 
difference in diameter, which affects the lateral profiles both on the surface and proximal to the 
plaque. These differences are less pronounced farther from the inner surface of the plaques. 
 A measured dose distribution of CIA 156 eye plaque is shown in Figure 14-a and a 
horizontal profile passing through the central axis of the dose distribution on Figure 14-a is shown 
in Figure 14-b. As can be seen in Figures 14-a and 14-b, the dose distribution of the CIA 156 eye 
plaque which is typical for eye plaques with a cutout has a maximum which is 23% higher than 
the dose at the central axis shifted about 3.0 mm laterally from the central axis. On the other hand, 
the data provided by the manufacturer with CIA eye plaques consists only of the dose rate on the 
central axis and of the surface dose rates measured at 33 points at a distance 1.0 mm from the inner 
concave surface. There is nothing in these data explaining or suggesting that there is a maximum 
shifted from the central axis, and, since most of the end users are using one-dimensional treatment 





Figure 14. a - measured dose rate distribution at distance 3.505 mm from the inner surface of the 
CIA 156 eye plaque. The distribution shown is a view from the plaque. The distance between grid 
lines is 0.5 cm. b - horizontal profile through the central axis of the dose distribution of the CIA 




Estimated uncertainties of the film measurements were analyzed using guidance provided by NIST 
Technical Note 129747167 and Mitch et al48168 Applications of uncertainty analysis to radiochromic 
film dosimetry in brachytherapy were discussed by Chiu-Tsao et al49141 and Soares et al38113.  Table 
2 provides the estimated uncertainties for single film response, Table 3 for film calibration and 
Table 4 for 106Ru eye plaque dosimetry using radiochromic film. Table 5 provides estimated 




























Table 2. Estimated uncertainties in a single film response. 
Component of uncertainty Uncertainty % Type 
Typical background film uncertainty  1.0% A 
Typical irradiated film uncertainty 2.0% A 
Uncertainty due to scanner stability, reproducibility, 
and temperature effects 
0.5% B 
Uncertainty due to lateral scanner response 
Correction not needed, since the films are small and 
always positioned at the center of the scanner bed.  
0.0% A 
Combined standard uncertainty for net optical density 2.3%  
 
Table 3. Estimated uncertainties in film calibration. 
Component of uncertainty Uncertainty % Type 
Uncertainty in a single film response from Table 2 2.3% A and B 
Uncertainty in Linac beam calibration, including ADCL 
chamber calibration uncertainty 0.7%, ADCL 
electrometer calibration uncertainty 0.1%, setup 
uncertainty 0.5% 
0.9% A and B 
Uncertainty in fitting parameters of the calibration 
curve 
1.5% B 
Combined standard uncertainty for film calibration 2.9%  
 
Table 4. Estimated uncertainties in 106Ru eye plaque dosimetry using radiochromic film. 
Component of uncertainty Uncertainty % Type 
Uncertainty in a single film response from Table 2 2.3% A and B 
Uncertainty in film calibration from Table 3 2.9% A and B 
Film non-uniformity 1.5% A 
Uncertainty in measurement depth 1.6% A and B 
Uncertainty in irradiation time 0.1% A 
Combined uncertainty 







The uncertainties in the measurement depth for the film and diode dosimetry were assessed as the 
mechanical uncertainties multiplied by the dose gradient on the central axis proximal to the eye 
plaque, which is on the average 26%/mm in the first 3.0 mm from the inner concave surface, 
resulting in the dosimetric change over the mechanical uncertainty distance. 
 
Table 5. Estimated uncertainties in 106Ru eye plaque dosimetry using a silicon diode. 
Component of uncertainty Uncertainty % Type 
Uncertainty in 106Ru eye plaque dosimetry using a 
silicon diode, as assessed by Lax1667 
4.5% A and B 
Uncertainty in effective measurement point position 
±0.15 mm from the diode certificate 
3.9% B 
Uncertainty in effective measurement point position 
due to water tank mechanism uncertainty 
5.2% A 
Combined uncertainty 
Combined, expanded (k=2) uncertainty 






Radiochromic film dosimetry of beta-emitting radiation sources has a long history. Soares50,51169, 
170, Sayeg and Gregory52171 and Soares and McLaughlin53142 used early radiochromic film for 
surface dosimetry of 90Sr/90Y ophthalmic applicators. The technique using early radiochromic 
films was applied by Taccini et al1971 and Soares et al1573 for dosimetry of 106Ru eye plaques which 
at that time had substantial dosimetric uncertainties and non-uniformities as described in the 
introduction. Taccini et al1971 used two different PMMA phantoms, one for placement of vertical 
films parallel to the central axis of the plaque and the other for horizontal films perpendicular to 
the central axis of the plaque and also used thin strips of film to measure surface doses and non-
uniformity. Taccini et al1971 did not report either substantial dose disagreements with the 
manufacturer’s data, or dosimetric non-uniformities, except of dose fall-off to less than 40% at the 
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1 mm region close to the rim of the plaques. Since the measurements were done during the period 
of known dosimetric problems of 106Ru eye plaques, it is possible that they had a good production 
series of eye plaques or maybe the technique was not sufficiently sensitive. Soares et al1573 
compared different measurement methods of beta-emitting ophthalmic applicators including 
measurements in a set of Solid Water phantoms designed for placing the films perpendicular to 
the central axis of the plaque. They observed a serious dosimetric non-uniformity at a concave 
106Ru eye plaque. The most recent publication by Heilemann et al24162 used a phantom setup similar 
to Taccini’s et al1971, a PMMA phantom enabling placing both vertical and horizontal films, but 
using mostly vertical films for dosimetry.   
The phantom presented in this work uses horizontal films perpendicular to the central axis of the 
plaques, similar to the phantom used by Soares et al1573, but has a few additional features helpful 
in clinical dosimetry, namely the rigid positioning of the eye plaque with respect to the films and 
the co-registration features enabling reconstruction of 3D dose matrix usable for either 2D or 3D 
treatment planning. Use of horizontal films enables irradiation of one film at a time, which has the 
advantage of selection of the “high contrast” steep dose range of the calibration curve, where the 
dosimetric uncertainty is less than using the decreased slope of the calibration curve at high doses, 
where a small change in pixel value results in a large change in dose. Using vertical films requires 
a large dynamic range of dose, since it has to cover the whole dose range from the surface of the 
eye plaque to the low doses at depth in one exposure, using the decreased slope of the calibration 
curve.  For example Heilemann et al24162 irradiated EBT3 films to doses between 15 and 18 Gy, in 
order to achieve “adequate dose levels even at distances of 12 mm from the plaque’s surface”, 
claiming that “no significant saturation effects were observed” and they used only the red 
component of the RGB image for film evaluation. The dose range of EBT3 film rated by the 
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manufacturer for use in the red channel is 10 Gy, and even this number is in the decreased contrast 
area of the calibration curve, so the uncertainty of this work for the higher dose areas in the 
proximity of the plaques should be fairly high. Generally using EBT3 film for dosimetry at doses 
above 10 Gy should be done in the green channel which enables extending the workable dose 
range of this film.    
 The unique film punches developed in the course of this work proved to be very valuable 
in precise cutting of films without splitting layers or damaging the edges even if cutting multilayer 
films.    
Hot and cold spots, as well as other dosimetric non-uniformities, like the ones found at the 
CCX 55 eye plaque may lead to overdosing critical structures, for example the sclera, or 
underdosing parts of the tumor, if not accounted for. Since treatment planning for ophthalmic 
tumors using eye plaques is mostly one-dimensional utilizing two-dimensional ultrasound images, 
an in-house computer program which would use the dosimetric data from the planar films was 
developed at MSKCC. The program would calculate for a given eye plaque for any given depth 
relative to the sclera and lateral distance r, relative to the central axis, the minimum dose along an 
annulus of radius r. These two-dimensional reduced dose distributions would be superimposed on 
the ultrasound images for clinical evaluation of the minimal coverage. Similar distributions for the 
maximal annular dose are used to prevent overdosing critical structures adjacent to the tumor. 
6. Conclusions 
 
Radiochromic film in a Solid Water phantom is a convenient, accurate, and reproducible dosimeter 
for 106Ru eye plaque dosimetry. Radiochromic films, especially the special single layer films, 
enable direct dose measurements on the inner surface of the plaques, providing precise assessment 
of the scleral dose, its uniformity, and of the active area of the plaques for coverage determination 
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and proper selection of plaques for treatment. The measured data may be used either by a 2D or 
3D treatment planning system, enabling one to account for dose non-uniformities and to protect 
critical structures. Cutting, preparation and handling of radiochromic films play an important role 
in precise absolute film dosimetry. Despite improved quality and dosimetry by BEBIG, the post 
2002 CCX plaques dosimetrically investigated in this work had central axis dose rates 6.0 – 11.4% 
lower than the manufacturer’s data and hot areas in the vicinity of the rim. The relative central axis 
dose rates were found in good agreement with Monte Carlo calculations by Hermida-López3379, 
while the lateral disagreements between calculated and measured results could be explained by 
deviations of the actual plaques from expected values. The radiation coverage on the surface of 
one of the plaques was found to end 1.25 mm (CCX 129) from the rim vs. 0.75 mm expected from 
the manufacturer’s specification.  Each 106Ru eye plaque must undergo accurate dosimetric 
commissioning and acceptance prior to its clinical use in the U.S. Because of the history of 
conflicting dosimetric results, it is important to clarify the source of the dosimetry used in the 
prescription protocol and it is the ultimate responsibility of the medical physicist and physician to 
decide what values to use for treatment delivery. 
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